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2- and 4-Halopyridines were previously identified as a novel class of protein 
modifiers.  These weakly electrophilic fragment sized molecules were shown to act as 
quiescent affinity labels that selectively and covalently modify some protein thiols. 
Covalent modification can occur when a carboxylate side chain is found at a certain 
distance and orientation from a cysteine thiol. This arrangement of residues catalyzes 
covalent bond formation by stabilizing the active, protonated form of the pyridine, which 
allows subsequent attack by the cysteine thiol.  This need for catalysis imparts a unique 
selectivity that sets 2- and 4-halopyridines apart from most electrophilic fragments since 
efficient modification is not only derived from inherent reactivity and proximity to the 
target nucleophile, but also by way of a protonation ‘switch’ catalyzed by two residues at 
the binding site of the target protein. The inherent selectivity of these fragment sized 
molecules and their relatively straightforward derivitization at multiple positions on the 
pyridine ring have prompted further study to characterize their unique features as a class 
of covalent protein modifiers and to explore their utility to engage therapeutic targets. 
 vii 
In this work, the features that set 4-halopyridines apart from other fragment-sized 
electrophiles are identified and characterized.  These studies revealed the protonation 
‘switch’ allows modulation of halopyridine reactivity through catalysis whereas the non-
enzymatic reactivity remains low an effect not obtainable with other electrophilic 
fragments.  After definition of the general requirements for protein modification and 
identification of methods to alter reactivity, additional protein targets that meet the 
requirements for 4-halopyridine modification are identified and validated.  Modification 
of one of the identified targets for 4-halopyridines, V-Ki-ras2 Kristen rat sarcoma viral 
oncogene (KRas), is characterized in detail.  It is demonstrated that the 4-halopyridine 
fragment represents a starting point to selectively modify this historically difficult drug 
target in cells. 
In a separate project, enzyme inhibition is studied and applied in a different way. 
The utility of a substrate-inactivatable Pseudomonas aeruginosa dimethylarginine 
dimethylaminiohydrolase (PaDDAH) mutant enzyme, PaDDAH T165L, for the 
quantitative measurement of asymmetric dimethylarginine (ADMA) is evaluated. The 
catalytic partitioning between normal turnover and self-inactivation enables a low cost 
quantitative means for measurement of the clinically-relevant biomarker ADMA. 
 viii 
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Chapter 1. Introduction 
The medicinal use of small molecules that function through the formation of 
covalent bonds has a long and storied history.  Acetylsalicyclic acid (aspirin) is one of the 
best-known and most widely used drugs that work by covalent inhibition of its target.  
The recorded origins of aspirin can be traced back to as early as 200 B.C. when the Greek 
physician Hippocrates prescribed willow tree extracts for pain relief. While the use of 
willow bark to combat pain and fever continued into the 19th century, the main active 
ingredient, salicyclic acid, was not isolated until 1838 by Italian chemist Raffaele Piria.1 
Within a half-century, the production, distribution, and use of salicyclic acid was 
widespread as was the gastric irritation that accompanied its regular use.2  A Bayer 
chemist, Felix Hoffmann, in 1897 synthesized a derivative of salicyclic acid, which 
effectively relieved the gastrointestinal distress associated with regular consumption of 
salicyclic acid.3  This derivative, acetylsalicyclic acid, was coined aspirin and while its 
use continues to this day, its mechanism of action remained a mystery for almost a 
century longer. 
In 1971, it was revealed that aspirin inhibits prostaglandin biosynthesis.4,5 
Synthesis of prostaglandins increases in response to local trauma. This causes elevated 
body temperature, inflammation, and pain. Aspirin was shown to act in part by 
acetylating, and irreversibly inactivating, both cyclooxygenase isoforms (COX-1 and 
COX-2), which are essential for prostaglandin synthesis.6  
The history of aspirin highlights many of the themes associated with the 
development of covalent drugs, one of the most common themes being serendipitous 
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discovery and confirmation of the covalent mode of action only long after the clinical 
utility had been well established.  For example, some of the most famous antibiotics 
(penicillin, cephalosporin(s), and fosfomycin) were discovered by fortuitous accident.7   
In the case of aspirin, the original acetylation of salicyclic acid was conducted not to 
convey any additional pharmacological effect when compared to the salicyclic acid, but 
merely to create a more palatable medicine.  Incredibly, acetylsalicyclic acid not only 
served as a prodrug for salicyclic acid, which has been shown to have its own COX-1/2 
independent anti-inflammatory effects, but also conferred irreversible inhibition of two 
principal proteins responsible for the local inflammatory response.8 
Regardless of the serendipitous circumstances surrounding their discovery, these 
examples clearly demonstrate the therapeutic utility of covalent drugs.  These early 
successes however, did not spur the rational development of covalent drugs in the modern 
era due to safety concerns surrounding irreversible and off-target binding.  Irreversible 
binding presents potential risks of idiosyncratic toxicity and/or immune-mediated drug 
hypersensitivity.  This response can cause the production of antibodies that target 
elements of the drug molecule itself or autoantibodies that recognize epitopes on drug-
modified proteins that are now rendered “foreign”.9,10  These rare adverse reactions, in 
addition to the ever-present (associated with both covalent and non-covalent drug 
development) risk of generating reactive drug metabolites during normal metabolism, 
have been enough to deter pharmaceutical companies from considering their 
development.11 In theory, the risks associated with off-target reactivity should decrease 
with decreased electrophilicity of the drug compound.  Evidence for this idea is 
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demonstrated by the successful development of acrylamide- and nitrile-containing 
compounds compared to compounds containing more reactive electrophilic functional 
groups such as epoxides and reactive Michael acceptors.10    
In the current landscape of structure based drug design, the incorporation and use 
of less-reactive electrophiles in targeted covalent inhibitor development has received 
renewed interest.  Structural information of the drug target aids in the optimization of a 
drug candidate’s non-covalent interaction in concert with placing a minimally reactive 
electrophile near a nucleophile of interest.9 The optimization of non-covalent interactions 
with the target is not only important for target selectivity, but also essential for efficacy 
because the low inherent reactivity of the electrophilic moieties (e. g. acrylamide) 
necessitates a high effective molarity of the electrophile for a facile reaction.  This 
development strategy continues to be used with moderate success, but the number of 
electrophilic moieties that fulfill the necessary requirements for incorporation into 
targeted covalent inhibitors and/or covalent drugs remains limited.  Expanding the 
number of well-characterized electrophiles available for the development of future 
targeted covalent inhibitors would be advantageous, but few novel protein-modifying 
electrophilic moieties have been discovered and applied in the last quarter century.   
In 2010, a high-throughput screen of fragment-sized inhibitors was carried out in 
an attempt to discover novel covalent modifiers of dimethylarginine 
dimethylaminohydrolase (DDAH).12  This screen identified 4-halopyridines (4-bromo-2-
methylpyridine and 4-chloro-2-hydroxymethylpyridine) as covalent inactivators of 
DDAH and were shown to represent a class of fragment-sized molecules that had not 
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been previously identified as covalent protein modifiers.  Characterization of the 4-
bromo-2-methylpyridine inactivation mechanism revealed that this fragment acts as a 
quiescent affinity label of DDAH meaning that inactivation is catalyzed by an off-
pathway mechanism by the target protein.  While unreactive towards non-specific 
nucleophiles (e.g. glutathione) in solution, the pyridine’s reactivity is greatly enhanced 
when the pyridinium form can be stabilized through protein binding and interaction with 
a nearby carboxylate.  Only when a protein nucleophile (e.g. thiol) is also correctly 
positioned at this binding site can modification occur.13 These constraints create an 
inherent selectivity for targets where all requirements are met.  Moreover, the necessity 
for pyridinium stabilization (termed the protonation ‘switch’) to promote nucleophilic 
aromatic substitution opens up the potential to modulate the electrophilic reactivity of the 
halopyridine scaffold in ways not available using other electrophiles. 
 
Figure 1.1 General Mechanism of 4-halopyridine protein modification.  
In Chapter 2, two methods in which the reactivity of the halopyridine scaffold 
can be modulated are explored.  The protonation ‘switch’ is hypothesized to allow 
reactivity to be uniquely tuned using pyridine nitrogen pKa modulation and halogen 
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identity.  Derivitization of typical electrophiles to increase reactivity also drastically 
increases non-selective reactions.14 However, 4-halopyridine ring derivitization is shown 
to lead to only slight changes in non-enzymatic reactivity, but to significantly tune the 
reactivity for its targets.  While the catalytic residues and the features of halopyridines 
required for protein modification have been characterized for inactivation of DDAH, they 
are not expected to be unique to the DDAH enzyme family.  To confirm that not only 
DDAH, but also a wider subset of the proteome can be targeted using this scaffold, 
Escherichia coli (E. Coli) lysates were treated with 4-halopyridine derivatives containing 
a latent handle for Western blot visualization.  The results provide evidence for our 
hypothesis and further highlight how the requirements for binding, pyridinium 
stabilization, and proximity to the nucleophile influence the scaffold’s reactivity. 
Affinity purification combined with mass spectrometry was previously used to 
identify primary screening ‘hits’ within the 2- and 4-chloropyridine proteomic subsets 
(unpublished).15   In Chapter 3, verification of selected targets within this dataset is 
carried out.  Of three targets chosen for validation, detailed characterization of the 4-
halopyridine target KRas is studied in detail.  KRas remains an elusive target for the 
treatment of cancer, but recent evidence suggests that covalent targeting strategies may 
provide a means to overcome some of the previously recognized hurdles in the 
development of direct Ras inhibitors.16,17 Characterization of modification by 4-
halopyridine derivatives revealed that KRas modification is similar to the mechanism 
previously shown for DDAH and E. Coli inosine monophosphate dehydrogenase 
(unpublished).15  However, unlike these previously characterized targets, the covalent 
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adduct to KRas is not stable in solution due to subsequent hydrolysis. Following in vitro 
characterization, the effects of 4-chloropyridine treatment of cultured MiaPaca2 cells 
harboring oncogenic KRas and validation of target engagement with KRas in cell culture 
were tested.  Although 4-halopyridine modification of KRas G12C was observed in this 
pancreatic carcinoma cell line, a robust functional effect on cell proliferation did not 
accompany 4-chloropyridine treatment.  An in vitro test for the extent of KRas 
modification suggests that one factor may be due to only a small fraction of total KRas 
being modified in cells.    This work demonstrates the ability to target and engage KRas 
using an inherently selective electrophilic fragment and represents a promising new 
strategy and starting point for KRas targeting. 
Chapters 2 and 3 study enzyme inactivation for the purpose of blocking their 
physiological activity. In, contrast, Chapter 4 presents work that uses enzyme 
inactivation as a quantitative analysis tool. The use of enzyme inactivation as a means for 
small molecule quantification is, to the best of our knowledge, a novel application not 
previously explored by others.  Preliminary work conducted by Dr. Tom Linsky and Dr. 
Corey Johnson in our laboratory showed a mutant form of DDAH, T165L, was 
covalently inactivated by its own substrate over time due to partitioning between normal 
substrate turnover and self-inactivation (unpublished).18 In Chapter 4, a methodology is 
developed to quantify Nω- Nω-L-dimethylarginine (ADMA), which is the native 
PaDDAH T165L substrate and is also a clinically relevant biomarker. As it pertains to 
assay development, the experimental partition ratios for the DDAH substrates, ADMA, 
Nω-monomethyl-L-argnine (NMMA), and S-methyl-L-thiocitrulline (SMTC) are 
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measured, and the influences on PaDDAH T165L reactivation (following inactivation by 
substrate) are evaluated. Proof-of-principal experiments demonstrate the feasibility of this 
approach for ADMA quantification. The general assay workflow is experimentally 
optimized and applied to the quantification of ADMA in clinical blood-plasma samples.  
The concept of using mutation-induced substrate-inactivation as a means for small 
molecule quantification introduced here, may be applicable to other biomarkers of 
interest where substrate partitioning has been reported or can be engineered.    
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Fragment-based drug discovery (FBDD) describes the method of identifying 
small molecules (ca. ≤250 Da) that bind a protein target and serve as starting points for 
further elaboration.  The effectiveness of this approach towards non-covalent inhibitor 
development is now well documented among a diverse set of protein classes including 
kinases, proteases, chaperones, and others.1-4  
The FBDD strategy is also advantageous in the design of targeted covalent 
inhibitors (TCI’s). In practice, once a non-covalent fragment scaffold is identified, 
structure-based and computational methods can be used to guide the elaboration of the 
compound in order to place an electrophilic moiety near a nucleophile of interest.5 
Optimizing non-covalent binding affinity first, enables less reactive electrophiles to be 
used, in turn, increasing the likelihood of quickly developing a selective inhibitor. This 
approach has been especially effective towards the design of kinase inhibitors that target 
non-conserved cysteine residues.6  
Recent drug development studies using TCIs often use acrylamides or substituted 
acrylamides as the electrophilic moiety to target the thiol of interest.  The relatively poor 
electrophilicity of acrylamides make them an attractive choice compared to other more 
                                                
1 Chapter 2 was adapted from the following manuscript: Schardon CL, Tuley A, Er J, Kenefick H, Swartzel J, Fast W. 
(2016) 4-Halopyridines: Selectively Electrophilic Fragments with a Tunable Switch. In preparation. A. Tuley , J. Er, J. 
Swartzel contributed to compound synthesis and H. Kenefick to experimental design. 
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reactive electrophilic moieties to avoid off target effects.  The increased reactivity of 
cyanoacrylamide derivatives also increases the reversibility of modification reducing 
some concerns about off-target modification.7   Still, it is unlikely that all thiols of interest 
can be effectively targeted using the acrylamide moiety due to the trade-offs between 
optimizing non-covalent interactions and properly orienting the electrophile for thiol 
attack.  The application of other fragments with advantages similar to those afforded by 
acrylamide (e.g. low inherent reactivity), but with enhanced selectivity would be 
advantageous. 
One scaffold, 4-halopyridine, was recently identified in an effort to find novel 
inhibitors of the nitric oxide-controlling enzyme dimethylarginine 
dimethylaminohydrolase (DDAH).8-10 For inhibition of DDAH, the 4-halopyridines were 
classified as quiescent affinity labels, indicating that catalysis (but not the normal DDAH 
mechanism) is needed for nucleophilic aromatic substitution at the 4- position under 
biological conditions.  In the case of DDAH, covalent modification can only occur 
because a carboxylate side chain is found at a certain distance and orientation from a 
cysteine thiol. This arrangement of residues stabilizes the active, protonated form of the 
pyridine, and subsequent attack by the cysteine thiol is thus catalyzed.10 Concisely, the 
reactivity and the selectivity of this fragment sized small molecule are interdependent, 
producing an inherent selectivity for targets where all requirements are met.  
These requirements set 2- and 4-halopyridines apart from most electrophilic 
fragments.  For example, when other weak electrophiles, like acrylamide, are 
incorporated into TCI’s, efficient modification is derived not from any change in 
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reactivity, but solely from the high effective concentration brought on through non-
covalent binding to the target.  In contrast, modification by the 4-halopyridine fragment 
relies on catalysis in addition to non-covalent binding and proper orientation. As such, 
the 4-halopyridine scaffold represents a unique electrophilic fragment (≤250 Da) whose 
reactivity and selectivity is defined by a simple protonation ‘switch’, catalyzed by 
residues in its target binding site.  
The simple structure and activation mechanism of 4-halopyridines suggest that 
this scaffold may be useful for a much wider array of applications in the design of 
molecular probes, enzyme inhibitors, and therapeutics.9 In this chapter, several aspects of 
this scaffold are explored and characterized in detail in order to facilitate their 
development as covalent modifying agents.  Specifically, we aimed to (1) define the rate 
enhancement afforded by the protonation ‘switch’, (2) determine the influences halogen 
species and (3) pyridine nitrogen pKa modulation have on inactivation and/or thiol 
modification rates (using hDDAH1 as a model enzyme), and (4) ultimately confirm the 
applicability of 4-halopyridines for use on a broader set of targets. 
 
2.2 MATERIALS AND METHODS 
Materials 
Unless noted otherwise, all chemicals are from Sigma- Aldrich Chemical Co. (St. 
Louis, MO). hDDAH1 was purified and assayed as described previously.11 4-Chloro-2-
metheyl-pyridine, 3-amino-4-bromo-pyridine, and 2-amino-4-bromo-pyridine were 
obtained from Chem-Impex International, Inc. (Wood Dale, IL). 3-Amino-4-iodo-
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pyridine and 4-bromo-2-methylpyridine were from Oakwood Chemical (Estill, SC). 2-
Trifluoromethyl-4-chloropyridine was from Ark Pharm Inc. (Libertyville, IL). and 4-
Chloro-3-carboxypyridine was from Enamine LLC. (Monmouth Jct., NJ). 
4-Halopyridine pKa Calculation  
 Pyridine nitrogen aqueous ionization constants (pKa) for all 4-halopyridines and 
derivatives used in this study were calculated using the pKa calculator plugin (default 
settings) in MarvinSketch Version 15.11.16.0.12-14   
Determination of 4-Halopyridine Relative Reactivity with Glutathione  
Reduced glutathione was incubated with compounds 1-8, and 29 at a 1:1 ratio (1 
mM each) in buffer containing 0.1 M NaCl, 0.15 M KH2PO4, 1 mM 
ethylenediaminetetracetic acid (EDTA) at pH 7.5 for 45 min.  Samples were quenched 
upon addition of 5,5’-dithiobis-2-nitrobenzoic acid (DTNB) to a final concentration of 
1.85 mM.  Buffer was added to each sample resulting in a total volume of 1.25 mL.  The 
absorbance at 412 nm was read for each sample to determine the amount of reduced 
glutathione remaining after the 45 min incubation. The amount of reduced glutathione 
was calculated using the extinction coefficient for DTNB at 412 nm in dilute buffer 
solutions, ε412= 14,150 M-1cm-1.15 
Determination of Reaction Rate for Thiophenol with Halopyridines  
Reduced thiophenol (1 mM) was incubated with compounds 8-16, 16m, 22-25, 
and 29 (10 mM) in buffer containing 0.1 M NaCl, 0.15 M KH2PO4, 1 mM EDTA at pH 
7.5.  Aliquots were removed from the incubations at various time points (20 uL, 0-80 
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min) and diluted into buffer solution containing DTNB (1.85 mM) for a final sample 
volume of 1 mL.  The absorbance at 412 nm was read for each time point to determine 
the amount of free thiol remaining (ε412= 14,150 M-1cm-1).  The observed reaction rates 
(kobs) were determined by fitting the percent reduced thiol remaining over time to a 
single-exponential equation. All fits were calculated using KaleidaGraph (Synergy 
Software, Reading, PA) 
Time and Concentration Dependent Inactivation Assays  
Assays were carried out as previously described10. The observed inactivation rates 
(kobs) were determined by fitting the percent remaining activity over time to a single-
exponential equation.  The resulting kobs values were then plotted against inactivator 
concentration to determine the second order rate constant for each compound tested.  All 
fits were calculated using KaleidaGraph (Synergy Software, Reading, PA) 
Preparation of Naïve Escherichia coli Lysates  
BL21(DE3) Escherichia coli (E. Coli) was grown in 500 mL Lysogeny Broth 
(LB) medium at 37 °C with shaking and harvested by centrifugation 1 h after transition 
into stationary phase (OD600 = 1.5).16 Cells were suspended in buffer containing 100 mM 
KCl / K2HPO4 at pH 8 supplemented with protease inhibitor cocktail (170 μg/mL 
phenylmethylsulfonyl fluoride (PMSF), 1 μg/mL Pepstatin A, 1 μg/mL Leupeptin)  and 
lysed by sonication (210 s total, 10 s pulse on/45 s pulse off, 70% amplitude).  
Labeling of Naïve E. coli Lysates  
Naïve E. coli lysates (80 μg total protein, determined by Bradford Assay) were 
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treated with 30 or 31 (1 mM each) in buffer containing 100 mM KCl / K2HPO4 at pH 8 at 
room temperature for 3 h.17 Following incubation, a biotin tag was selectively attached to 
alkyne groups via the click reaction described below. 
General Procedure for Cu(I)-catalyzed Azide-alkyne Click Reaction.   
A biotin tag was selectively appended to alkynes in the reaction mixture by 
treating samples with N-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethyl]hexahydro-2-oxo-
(3aS,4S,6aR)- 1H-thieno[3,4-d ]imidazole-4-pentanamide (Biotin-PEO3-azide, 100 μM), 
tris(2-carboxyethyl)phosphine (TCEP, 1 mM), tris[(1-benzyl-1H-1,2,3-trazol-4-
yl)methyl]amine (TBTA, 100 μM), and CuSO4 (1 mM), making the final reaction volume 
50 μL. Samples were gently vortexed and allowed to react for 1 h at room temperature. 
Reactions were quenched by adding standard 4 × sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) loading buffer. Samples were separated by 1D SDS-
PAGE and analyzed by Western blot as described below. 
Western Bloting  
Western blots were performed by standard procedures using two primary 
antibodies, IgG fraction monoclonal mouse anti-biotin (1:200, Jackson ImmunoResearch, 
West Grove, PA) coupled with the Odyssey IR Dye Western Blot Kit I (Li-Cor 
Biosciences, Lincoln, NE), which contains IR Dye 800CW goat anti-mouse secondary 
antibody (1:10000). Images were scanned using an Odyssey Infrared Imaging System 
(Li-Cor Biosciences, Lincoln, NE) at the core DNA Facility (University of Texas, 
Austin). 
 15 
2.3 RESULTS AND DISCUSSION 
Despite the concerns involving off-target-reactivity and the potential for drug-
induced toxicity associated with the development of covalent drugs, their utility for 
improving human health has become more widely appreciated in recent years.5 This is 
reflected by both the increase in clinical trials for, and FDA approvals of, covalent 
drugs.18,19 As mentioned, a number of current covalent inhibitors use acrylamide as the 
electrophilic moiety because of its low reactivity compared to other electrophiles.  The 
adoption of alternative electrophilic fragments for the development of TCIs would call 
for the conservation of low intrinsic reactivity as well as the offer of other advantages.  
We reason that the 4-halopyridine scaffold represents a novel tool in this respect based on 
its simple, tunable, protonation ‘switch’.  
Glutathione Reactivity Comparison 
In an attempt to relate the reactivity of 4-halopyridines with other electrophilic 
fragments including acrylamide, representative electrophile fragments from FDA 
approved drugs, as well as more reactive electrophiles commonly used in protein 
modification, were tested for their ability to be modified by reduced glutathione (GSH) at 
pH 8. 20-23 Both 4-chloropyridine (8) and drug fragment representatives showed no 
observable modification by GSH under these conditions.  In contrast, the protein 
modification reagents showed modification by GSH and the extent of reaction reflected 
each compound’s relative reactivity (Figure 2.1).   
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Figure 2.1 Relative reactivity of electrophiles against glutathione. Percentage of 
reduced glutathione remaining after 45 min incubation at equimolar concentrations 
(1 mM) of compound and glutathione normalized to a no compound control. 
(Compound names and structures can be found in Table 2.1 and 2.2) 
One of the unique features of the 4-halopyridine scaffold is the necessity for 
stabilization of the pyridinium (the protonated pyridine) to catalyze nucleophilic attack.  
This protonation ‘switch’ can be mimicked chemically through N-methylation.  To 
represent the fully reactive 4-halopyridine, 4-chloro-N-methyl-pyridine (29) was tested 
for the ability to be modified by GSH.  When the pyridinium form is fixed by N-
methylation, the halopyridine compounds instead showed increased reactivity 
comparable to protein modification reagents such as iodoacetamide (5).  
 These results highlight the ‘quiescent’ quality of this scaffold.  At physiological 
pH values the 4-halopyridines show no measurable reactivity, similar to the low 
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reactivity of electrophiles currently used in TCIs.  However, unlike classical affinity 
labels, substantial selectivity is achieved just by the fragment moiety itself.  In other 
words, its electrophilicity is enhanced by the binding pocket (enzyme stabilization of the 
pyridinium form), and thus has enhanced reactivity through catalysis, not just by a high 
effective concentration.  
Protonation ‘Switch’ Rate Enhancement Quantification  
This 4-halopyridine protonation ‘switch’ represents a simple catalytic step that 
greatly influences the reactivity (and selectivity) of the 4-halopyridine scaffold.  We 
reasoned that by quantifying the maximum possible rate enhancement afforded by this 
‘switch’, we could define an upper limit on the effect catalysis can have on promoting 
modification. That is, when the optimal conditions are encountered, what increase in 
reactivity can be expected? To accomplish this, an analogous assay to the one used in the 
electrophilic fragment comparison panel was employed.  As previously noted above, 
GSH is not able to modify the 4-chloropyridine to any observable extent under these 
experimental conditions.  Therefore, the stronger thiol nucleophile thiophenol (pKa = 
~6.6) was used instead.24 Reaction of thiophenol with 4-chloropyridine (8) was 
observable under these experimental conditions, using saturating amounts of 8 over long 
time periods (0-80 min). To measure the maximum rate enhancement achieved by the 
pyridinium form, 4-chloro-N-methylpyridine (29) was used.  A 3.7 ± 0.2 × 103-fold 
increase in kobs was observed when comparing the kobs of 8 to the protonated mimic, 29  
 18 
Figure 2.2 Reaction rate of thiolphenol (1 mM) under saturating conditions of 
compounds 8 (l  , 10 mM) and 30 (n , 10 mM). Single exponential fits of compound 
8 and compound 30 give kobs values of -7.58 +/- 0.37 x 10-3 min-1  and -3.13 +/- 0.07 x 
101 min-1, respectively.     
 (Figure 2.2). At the concentration of 8 used in these experiments (10 mM), 
approximately 3 μM will be found in the protonated form.  Interestingly, the kobs ratio 
between 8 and 29 is in the same range as the ratio of protonated to deprotonated fractions 
of 8 at neutral pH suggesting the N-methyl analog is a good mimic for the protonated 
pyridinium. 
In this simplified, non-enzymatic model reaction, a rate enhancement of almost 
4,000-fold is achieved upon formation of the pyridinium ion.  In this case, we used a 
highly reactive nucleophile under saturating conditions of 8 in order to quantify this non-
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specific background reactivity. This analysis gives an approximation of the reactivity 
enhancement that can be achieved by way of the protonation ‘switch’.  
With respect to further development and use of this scaffold, these results show 
that unactivated 4-halopyridines, like acrylamide, are weakly electrophiles likely to show 
little non-specific off target reactivity. However, modification by the 4-halopyridine 
scaffold upon pyridinium stabilization, as catalyzed by the target protein, can enhance 
reactivity approximately 4,000-fold. The protonation ‘switch’ affords additional 
selectivity as well as unique ways to tune its reactivity.  Specifically, we reason that 
through derivitization of the pyridine ring and substitution of the halogen species, the 
reactivity, and thus the value of the protonation ‘switch’ can be tuned. In future 
embodiments, this tunable electrophilic fragment can be combined with other non-
covalent binding moieties to construct very selective TCIs.  
Halogen Dependence on Inactivation   
The inactivation of Pseudomonas aeruginosa dimethylarginine 
dimethylaminohydrolase (PaDDAH) by both a 4-bromo and 4-chloropyridine derivatives 
was reported previously during the discovery of the 4-halopyridine scaffold as a novel 
covalent protein modifier.11, 12 Therefore, it was apparent that the PaDDAH active site 
could accommodate different halogens, but its influence was not characterized. Here we 
investigate this influence in detail to provide data on how halogen substitution can be 
expected to effect covalent modification in the development of 4-halopyridine based 
covalent modifiers.  
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To explore the effect of halogen identity on enzyme inactivation, the 4-X-pyridine 
(X = Cl, Br, I) series was tested for the ability to inactivate human dimethylarginine 
dimethylaminohydrolase isoform 1 (hDDAH1). Of note, 4-fluoropyridine was found to 
be unstable in aqueous solution over the time period of the experiment and was therefore 
excluded from the series (data not shown). All 4-halopyridines showed time- and  
concentration-dependent inactivation.  The concentration dependence of inactivation 
rates did not show saturation kinetics, but rather showed a linear dependence on inhibitor 
concentration (Figure 2.3).  4-Bromopyridine (9) was shown to be the most effective  
 
Figure 2.3 Time and concentration-dependent inactivation of hDDAH1 by 9. (A) 
Exponential fits to the observed hDDAH1 inactivation at concentrations of 9: 375 
μM (l), 500 μM (×), 1 mM (q), 2.25 mM (u), 2.5 mM (+), 4 mM(z  ) (B) 
Concentration dependence of the pseudofirst-order kobs values give a second order 




Figure 2.4 Concentration-dependent inactivation of hDDAH1 by 8 (l), 9 (q), and 
10 (u) at pH 7.5. Concentration dependence of the pseudo first-order kobs values for 
compounds 8-10 give second order rate constants of 7.67 +/- 0.83 x 10-2 M-1sec-1, 3.58 
+/- 0.22 x 10-1 M-1sec-1, 2.83 +/- 0.18 x 10-1 M-1sec-1, respectively. 
hDDAH1 inactivator.  The kobs for inactivation by 4-iodopyridine (10) showed a 20% 
reduction when compared to 4-bromo, and 4-chloropryidine (8) was found to be 
significantly slower than either 4-bromo or 4-iodopyridine (Figure 2.4).  
 The calculated pKa of these 4-halopyridines only deviates by an estimated 0.05 
units, suggesting insignificant differences between the protonated fractions of each 
halogen species in solution.12  If the first step in the mechanism, nucleophilic attack by 
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the cysteine thiol, were rate limiting one would not expect to see a difference in the 
inactivation rates of 8-10. (Figure 2.5)  Conversely, if sigma complex (tetrahedral 
reaction adduct between the 4-halopyridine and cysteine thiol) collapse and concomitant 
halogen  ion release were rate limiting, a halogen dependent effect would be expected. 
These experiments revealed a significant halogen dependent effect on inactivation (Br > I 
>> Cl), suggesting halogen ion release is indeed rate limiting.24 However, the fact that 4-
bromopyridine inactivates hDDAH1 faster than 4-iodopyridine could mean that there are 
size constraints imparted by the hDDAH1 active site that limit the rate of inactivation by 
4-iodopyridine.  Alternatively, if the rate of formation of the sigma complex and the rate 
of subsequent collapse and halogen release are comparable in this simple catalytic 
mechanism, 4-bromopyridine may represent the optimal halogen yielding both an  
Figure 2.5 General mechanism of 4-halopyridine protein modification. 
electron deficient 4-carbon (compared to 4-iodopyridine) and providing adequate leaving 
group stability (compared to 4-chloropyridine).  While the underlying reasons for this 
observed order were not investigated in depth, these results do illustrate that the halogen 
species plays a significant role on the rate of catalysis. The results are also in agreement 
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with our current understanding of the mechanism.  Specifically, cysteine nucleophilicity 
is not the predominating factor in reactivity. As such, stabilization of the pyridinium form   
could effectively lower the energy barrier to the point that nucleophilic attack, and 
formation of the sigma complex, is no longer rate limiting.  
A broader search of literature describing the influence of halogen species during 
nucleophilic aromatic substitution reactions involving 4-halopyridine compounds found 
conditions almost entirely limited to reaction in organic solvents, using potent ionized 
nucleophiles, at high temperatures.25-27 These are drastically different conditions than our 
experiments, making direct comparisons potentially problematic.  Still, it is worth noting 
our observed trend is opposite to what might be expected on the basis of non-enzymatic 
SNAr reactions with pyridine, as measured in organic solvents, wherein polarization of 
the carbon-halogen bond is the determining factor in halogen replacement.25 
Enzymatically, a similar reverse trend was reported for inactivation of Actinobacter sp. 4-
CB-1 4-chlorobenzoyl-CoA dehalogenase, but in this case the SNAr reaction involves 
catalysis by an enzyme specific for this reaction carried out on a benzene ring (i.e. no 
protonated species stabilization required).28 Here we describe a simple protonation event, 
not likely to be specific to any particular enzyme class. Therefore, to the best of our 
knowledge, our results detail the first report of halogen influence on enzyme catalyzed 4-
halopyridine modification under biologically relevant conditions. 
hDDAH1 inactivation by a Diverse Set of Substituted Halopyridine Derivatives 
Given the importance of protonation for activating the pyridine electrophile, we 
sought to understand how this proton ‘switch’ can be tuned by substituents on the 
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pyridine ring and how this modulation is potentially advantageous in the development of 
TCI’s and other covalent modifiers.   
We hypothesized that increasing nitrogen pKa through ring derivitization would 
lead to increased inactivation rates by decreasing the barrier to protonation. To test this 
hypothesis, a series of commercially available substituted 4-halopyridine derivatives were 
purchased.  Time-dependent inactivation of hDDAH1 was carried out at several 
concentrations for each compound in order to define the second order inactivation rate for 
each derivative (Table 2.1, 2.2, end of chapter).  In all cases, there was no evidence of 
saturation kinetics at the concentrations tested (≤4 mM). Of the derivatives tested, the 2- 
methyl, 2-methanol, and 3-amino substitutions resulted in increased second order 
inactivation rate constants (M-1sec-1) compared to their respective un-substituted scaffolds 
(Figure 2.6).  Regardless of substituent the same halogen dependence was observed.  That 
is, for derivatives with common ring substituents the inactivation rates always followed 
the trend Br > I > Cl.   As mentioned, a small set of substituents tested resulted in 
increased inactivation, however, the relationship between inactivation rates and 
calculated pKa values was not straightforward.  Although only small substituents were 
used to minimize unfavorable steric effects, the steric and charge effects of the  
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Figure 2.6 Second order rate constants (M-1sec-1) of commercially available 4-halo-
pyridine derivatives by pyridine nitrogen pKa. Compounds are organized by 
halogen species 4-Cl (l), 4-Br (q), and 4-I (u).  Second order rate constants were 
defined by exponential fits of time-dependent inactivation of hDDAH1 at multiple 
concentrations up to or >4 mM. 2-pyridinyl-MeOH, 2-methyl, and 3-amino 
containing derivatives resulted in enhanced inactivation compared to their parent 4-
X-pyr scaffolds.  
derivatives may not be completely eliminated with hDDAH1 and may complicate the 
observed trends.  
The influence of ionized 4-halopyridine substituents on interactions with the 
hDDAH1 active site was demonstrated by the inactivation rates of 16 and 16m.  These 4-
chloropyridine derivatives only differ by conversion of the carboxylic acid to the methyl 
ester (Table 2.2).  Therefore, compound 16 and 16m have similar sterics, but 16m is not 
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anionic.  The calculated pKa values of 16 and 16m are 4.65 and 1.15, respectively.12  In 
terms of the pyridinium switch, based on our hypothesis we would expect the inactivation 
rate of 16 to be significantly increased when compared to 16m. However, we see the 
opposite.  16 does not show any measurable inactivation at 4 mM, instead, 16m shows 
inactivation under the same conditions. (Figure 2.7)  One interpretation of these results 
would be that potential pKa modulation via substituent identity is counterproductive if the 
derivitization blocks productive binding and orientation at the active site.  The hDDAH1 
active site has two carboxylates that presumable disfavor interaction with 16, but not with 
16m. Ideally, optimization of 4-halopyridine inactivators can be guided with respect to 
both non-covalent target affinity and by modulating the sensitivity of the protonation   
‘switch’.  Since small, uncharged substituents at the 2- position appear to be tolerated, we 
next focused on a series of 2-substituted 4-halopyridines to determine the effect of pKa 
modulation and avoid the steric issues described above.  
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Figure 2.7 Time-dependent inactivation of hDDAH1 by 16 and 16m at 16 shows no 
inactivation of hDDAH1 (l). Elimination of the negative charge through conversion 
to the carboxy methyl ester (q) results in inactivation at the same concentration 
and gives a kobs value of -5.91 +/- 0.05 x 10-3 min-1.   
hDDAH1 Inactivation by a Fluoro-methyl Series  
To more directly characterize the effect of nitrogen pKa modulation on enzymatic 
inactivation, a series of 4-chloro-2-fluoromethylpyridines were synthesized and tested.  
Fluorine is much more electronegative than hydrogen, but is comparable to hydrogen 
with respect to both van der Waals radius and carbon-bond length. Replacing a hydrogen 
atom for a fluorine atom can be expected to have a large electronic effect on nearby 
carbon centers with little overall change in steric bulk. After reviewing potential steric 
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interactions described above, this set of halopyridines allowed us to plot the log(kobs) 
versus pKa for this series and a linear relationship was observed over 4 orders of 
magnitude (Figure 2.8). This relationship describes how an increase or decrease in 
pyridine nitrogen pKa affects reactivity, as gauged by kobs.  Interestingly, when the  
 
Figure 2.8 log(kobs) v pKa for conservative 2-Fluoro-Methyl Series and parent 
scaffold, 8. log(kobs)  dependence on pKa is defined by the linear relationship, y=-2.9 + 
(0.49+/-0.4)x.   
commercial derivatives that did show measurable inactivation are revisited and plotted in 
the same way, respective of their halogen species, similar slopes are observed (Figure 
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2.9). These results further support our hypothesis and the mechanism for 4-halopyridine 
activation, in that tuning the pKa to high values can increase reactivity predictably.  
 
Figure 2.9 log(kobs) v pKa for commercially available 4-halo-pyridine derivatives with 
measureable inactivation rates.  The linear relationship between log(kobs) and pKa for 
4-Cl-R-pyr (l) is defined by y=-2.8 + (0.48 +/- 0.06)x and y=-2.5 + (0.48 +/- 0.03)x 
for 4-Br-R-pyr (q).   
Careful consideration of the tunable nature of the protonation ‘switch’ suggests 
potential applications for this scaffold.  Our data supports our hypothesis that increasing 
or decreasing nitrogen pKa through ring derivitization can modulate reactivity by 
adjusting the barrier to protonation both when target bound and when free in solution.  
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Increasing or decreasing the fraction protonated in solution will in practice reduce or 
increase the necessity for catalysis by the target to form the pyridinium during 
modification. This is a powerful tool for the design of a variety of different tools from 
TCI’s to proteomic profiling agents.  In practice, elaboration of this scaffold can be used 
to target specific enzymes and the reactivity of the scaffold can be tuned based on the 
selectivity needed for any particular application.  
Substituent Effects on Non-Enzymatic versus Enzymatic Reactivity  
Using the same experimental conditions described earlier for model studies to 
quantify the value of the protonation ‘switch’, the effects of 4-halopyridine derivitives 
used for hDDAH1 inactivation above, were now tested non-enzymatically (Compound 19 
and 20 were excluded due to solubility issues at >5 mM).  These experiments were 
carried out to determine whether derivitization also affects non-enzymatic reactivity and 
if the same relative reactivity trends are observed. If the same increases and/or decreases 
in reactivity are seen across all compounds (or at least those shown to inactivate 
enzymatically) this would suggest that derivitization affects general reactivity rather than 
having an effect specific to catalysis by hDDAH1.  
 While no substituent-based change in reactivity was seen when using GSH as the 
small molecule thiol, differences in reactivity can be observed by using a better 
nucleophile, thiophenol (Figure 2.10, 2.11A). Non-enzymatically, compounds 12 and 16 
showed the highest kobs values at 2.5 ± 0.1 × 10-2 min-1, 4.8 ± 0.2 × 10-2 min-1 respectively.  
However, enzymatically these two compounds showed little and no hDDAH1 
inactivation (Figure 11B).  With respect to 16, this difference is most likely due to 
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unfavorable charge interactions between the compound and the active site, as discussed 
above.  Based on our hypothesis, compound 12 was not predicted to be a strong 
hDDAH1 inactivator due to a large downward pKa shift exerted by the 3-carbonitrile 
group. For hDDAH1 inactivation 12 accordingly had a kobs value two orders of magnitude  
Figure 2.10 Relative reactivity of halo-pyridine derivatives toward glutathione. 
Percentage of reduced glutathione remaining after 45 min incubation at equimolar 
concentrations (1 mM) of compound and glutathione normalized to a no compound 
control.  No significant changes in reactivity are observed as a function of 
derivitization.   
lower than 4-bromopyridine.  However, the non-enzymatic reactivity of 12 with 
thiophenol is relatively high (Figure 2.11A). All other compounds are clustered between 
kobs values of 0-0.015 min-1.  One interpretation of the data is that because of the demand 
for pyridinium stabilization to promote modification, the protonation ‘switch’ is acting in 
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a gated manner. That is, without pyridinium stabilization, nucleophilic attack is rate 
limiting and represents a large energy barrier regardless of the given compounds pKa.  
Only when the protonated form can be stabilized through target binding is the effect of 
pKa modulation realized.  However, from this data alone, we cannot exclude the 
possibility that a different mechanism may be at work non-enzymatically versus 
enzymatically.  
 
Figure 2.11 (A) kobs (min-1) of thiol reactivity for commercially available 4-halo-
pyridine derivatives by pyridine nitrogen pKa. kobs rate constants were defined by 
single exponential fits of remaining thiol over time (0-80 min). (B) hDDAH1 
inactivation kobs (min-1) at 10 mM for comparison. kobs rate constants were estimated 
based on second order rate constants. Compounds are organized by halogen species 
4-Cl (l), 4-Br (q), and 4-I (u).   
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Above, we assumed a nucleophilic SNAr reaction, but radical reactions might also 
be possible as have been reported for 2-halopyridines using a benzenethiolate anion in 
organic solvent. So, to quench any radicals produced in the reaction, we preformed 
experiments in the presence of narengenin, a bio-available free-radical scavenger (Figure 
2.12A).27, 29,30 The results showed no change in reactivity trends indicating that this 
mechanism is not radical dependent in aqueous solution and the assumption of the 
nucleophilic SNAr reaction mechanism is reasonable.  
Differences in compound reactivity trends between enzymatic and non-enzymatic 
studies might indicate that different rate determining steps matter in each case.  However, 
 
Figure 2.12 Halo-pyridine non-enzymatic and enzymatic reactivity in the presence 
of a free-radical scavenger. (A) Reaction rate of thiolphenol (1 mM) under 
saturating conditions of 9 (S  ,10 mM) and 9 + Narengenin (vu  , 10 mM). (B) 
Time-dependent inactivation of hDDAH1 by 8-10 + Narengenin (10 mM).  Single 
exponential fits of 8 (l , 5 mM), 9 (q , 2 mM), and 10 (u , 2 mM) give kobs values of -
0.025 +/- 0.001 min-1, -0.039 +/- 0.001 min-1,  and -0.030 +/-0.001 min-1, respectively. 
Both the halogen dependence and inactivation rates are consistent with experiments 
lacking narengenin.  
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the individual rate constants for reactivity of the 4-halopyridines with thiophenol were 
not investigated and the lack of published literature on non-enzymatic SNAr reactions 
involving pyridine in aqueous solution limits the ability to draw conclusions on the nature 
of 12 and 16’s enhanced reactivity. What can be said is that both 12 and 16 contain strong 
electron-withdrawing groups (EWG). The enhanced reactivity of these derivatives is in 
agreement to what is observed with respect to organic synthesis, where replacement of 
halogen atoms in aryl halides by RS groups is facilitated when the aromatic ring contains 
strong EWGs, like those found in 12 and 16, but is in stark contrast to the electron-
donating group (EDG) substituents that result in increased hDDAH1 inactivation (2-
MeOH, 2-Me, 3-amino).  
 
Figure 2.13 MS Zoomed Spectrum of thiophenol and 4-bromo-3-carbonitrile 
incubated overnight.  
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One alternative explanation of the enhanced reactivity of 12 is that thiophenol is 
not replacing the halogen, but instead reacting with the carbonitrile, resulting in imine 
formation.  We preformed mass spectrometry (MS) analysis on incubations of 12 with 
thiophenol to determine if the imine adduct was formed overnight. (Figure 2.13) No m/z 
corresponding to the imine adduct was found, only the reaction product produced upon 
halogen replacement by thiophenol.  
What can be said with confidence in the comparison of these two data sets is that, 
excluding compounds 12 and 16, non-enzymatic reactivity was weak and clustered across 
a broad pKa range trending proportionally with increased pKa.  In addition, the 
compounds that did show increased non-enzymatic reactivity were not in agreement with 
those found to be increased enzymatically.  While our data supports our pKa modulation 
hypothesis with respect to enzymatic modification, where protonation plays a key role, 
other factors may have a stronger influence on non-enzymatic reactivity, but the 
underlying reasons were not investigated fully here.  
Proteomic Profiling by 4-Chloropyridine and 4-Chloro-N-Methyl-pyridine Probes  
To this point, we have explored the characteristics and unique features of halo-
pyridines as electrophilic scaffolds for use in the development of TCIs and other covalent 
probes, using a model enzyme studied extensively in our laboratory. However, the 
requirements for protein modification by 4-halopyridines are not expected to be unique to 
the DDAH enzyme family, but would be expected to impart an inherent selectivity for an 
unknown subset of targets where all requirements are met. A recent communication 
investigating the proteomic reactivity and selectivity of aryl halides, including both 2-
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chloropyridine and 2,4-chloropyridine probes, initially confirmed their broader 
application, but noted their significantly decreased reactivity relative to the other aryl   
halides tested.31 While this report provides strong evidence for our hypothesis, here we 
sought to determine other targets of 4-halopyridine modification.  
To do so, E. Coli lysates were treated with either an alkyne-bearing 4-
chloropyridine probe (30) or a fully activated N-methyl version of the same (31). 
Following incubation, a biotin moiety was appended to the alkyne using standard Cu(I)-
catalyzed azide-alkyne cycloaddition.  Lysates were then separated by SDS-PAGE, and  
Figure 2.14 Covalent modification of proteins in E. coli lysates by 30 and 31. Lysates 
were treated with Compound (1 mM) for 3 h, followed by biotinylation. (A) 
Coomassie Stain of E. Coli Lysates treated with (1) No compound, (2) Compound 30 
following heat treatment, (3) Compound 30, (4) Compound 31, (5) Compound 31 
following heat treatment. (B) Western blot of naïve E. coli lysate of the same. 
Visualization using an Mouse α-Biotin mAb and GαM Secondary Ab detection 
(green signal) , MW Ladder (red signal) 
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visualized via Western Blot using an anti-biotin fluorescently conjugated antibody.  In 
order to demonstrate the necessity of target binding and pyridinium stabilization for 
protein modification by 30, but not 31, E. Coli lysates were heat treated in parallel prior 
to treatment with compounds 30 and 31.  Visualization of the Western Blot shows a 
subset of the proteome is modified by the alkyne bearing 4-halopyridine probe. 
Furthermore, this subset is significantly less than that labeled by the fully activated N-
methyl version.  Finally, heat denaturation resulted in a loss of labeling with 30, but an 
increase of labeling by 31.  (Figure 2.14B)  
These results confirm that there is a distinct subset of the proteome that can be 
targeted using this scaffold. An important observation is that only a small portion of the 
proteome is labeled with 30 as compared to 31 and that no proteins are labeled by 30 
after heat treatment. Therefore, if the protonation ‘switch’ is always on, eliminating the 
need for pyridinium stabilization all together, the probe becomes non-selectively reactive 
as evidenced by increased protein labeling. Along the same lines, if protein structure is 
compromised, eliminating proper target binding and catalysis by the correctly positioned 
cysteine thiol, modification by 30 is lost. Conversely, heat denaturation does not 
eliminate modification when pyridinium stabilization is not necessary (31), but results in 
a further increase in labeling.  Most likely, the increase in labeling is due to increased 
accessibility to protein thiols upon denaturation.  It is therefore reasonable to conclude 
that for the modified proteins visualized using 30, the basic requirements for 4-halo-




In this chapter we have identified and characterized the features of the 4-halo-
pyridine scaffold that allow its reactivity to be tuned including halogen identity and 
pyridine nitrogen pKa modulation.  The protonation ‘switch’ provides a potential 4,000-
fold tunable switch to enhance reactivity that can be catalyzed by the target, This 
property sets the 4-halopyridines apart from other fragment electrophiles.  In other cases, 
derivitization of electrophilic fragments to increase electrophilicity will also increase 
non-selective reactions. In contrast, 4-halopyridine ring derivitization leads to only slight 
changes in non-enzymatic reactivity toward biological nucleophiles like GSH. However, 
it can change the ability for the target to catalyze protonation. The requirements for 
protein modification by the 4-halopyridine scaffold limit the number of possible targets, 
but uniquely allow for modulation of its reactivity through catalysis independent of 
drastic changes in non-enzymatic reactivity as would be unavoidable with other 
electrophilic fragments.32  
While these features have been elucidated using hDDAH1, it is likely that the 
general guidelines outlined here will be applicable to other enzymes modified by 4-
halopyridines. Identifying and evaluating other therapeutically relevant targets within this 
subset is one goal of our current research efforts.  Along with the ability to achieve high 
effective concentrations through non-covalent elaboration as is done with other TCIs, the 
4-halopyridine scaffold’s unique selectivity and tunable features make it a valuable tool 
for fragment-based approaches. The insights gained herein will help to guide the 
development of 4-halopyridine based covalent modifiers.  
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Table 2.1 Summary of halo-pyridines evaluated to investigate influence of halogen 
species and pKa modulation on inactivation rates. 
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Table 2.2 Structures of 4-halopyridine derivatives evaluated for hDDAH1 inactivation 
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Chapter 3:  Evaluation and Characterization of Selected 




 As detailed in Chapter 2, the 4-halopyridine scaffold was first identified as a 
novel covalent modifier in an effort to discover structurally diverse inhibitors of 
dimethylarginine dimethylaminohydrolase (DDAH).1,2  Characterization of this 
inactivation mechanism revealed that binding to the protein target stabilizes a more 
reactive protonated form of the pyridine via a correctly positioned carboxylic side chain 
(Asp66 in DDAH).  This protonation facilitates nucelophilic aromatic substitution (SNAr) 
by a neighboring cysteine.  Based on these requirements for covalent modification by 4-
halopyridines it was hypothesized that other targets might also be susceptible to covalent 
modification by the 4-halopyridine scaffold and that similar compounds may be useful in 
the design of molecular probes, enzyme inhibitors, and therapuetics.2   
This hypothesis was tested in our laboratory by conducting an E. Coli proteomic 
screen using 2- and 4-chloropyridines modified with an alkyne as a latent handle 
(unpublished). After labeling of E. Coli lysates and selective biotinylation of labeled 
proteins using standard Cu(I)-catalyzed click chemistry, proteins that were covalently 
labeled were partially purified using streptavidin affinity purification.  Mass spectrometry 
(MS) was used to identify the enriched proteins. The identified proteins were treated as 
primary screening ‘hits’ and contain a variety of different protein classes.  
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Verification of targets within the primary hit list is sought for several reasons.  
First, follow-up experiments are needed to validate the ability of halopyridine(s) to 
covalently modifiy the target protein of interest.  Affinity purification combined with 
mass spectrometry is a well established procedure to identify target enrichment based on 
a given treatment.  However, nonspecific interactions with the affinity column matrix or 
with the retained proteins can lead to false positives.3 Additionally, during the protomic 
screening procedure, parameters such as redox state and protein abundance were not 
explicitly controlled or normalized for.4-6  Validation of primary ‘hits’ is therefore 
essential for confirmation.  Secondly, while the initial characterization of the 
halopyridine scaffold indicated a correctly positioned carboxylic side chain and cystiene 
nucleophile were required to catalyze inactivation of DDAH it’s not clear if this residue 
configuration is the only way to catalyze covalent bond formation.  Determining if the 
requirments previously outlined for target modification hold true for additional targets 
would help to reveal if covalent modification using this scaffold is stringent with respect 
to the previously outlined mechanism or if there are any other sites that could be targeted 
by halopyridines.    Together, validation and characterization of additional targets builds 
evidence for the application of halopyridines as a useful inhibitor scaffold.  
The primary proteomic screen of E. Coli lysates resulted in 142 hits identified in 
the 2-chloropyridine (1) and/or 4-chloropyridine probe (2) samples, but not the no probe 
control. Narrowing these hits to fewer candidates for further validation was carried using 
several criteria. First, proteins were selected based on their clinical or therapeutic 
significance.  Secondly, proteins with catalytic functions were selected to facilitate 
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characterization by kinetic assays.  Third, similarity between each enzyme’s substrate and 
the halopyridine scaffold was considered in an attempt to increase the likelihood of 
validating active site modifiers.  Fourth, crystal structures of the remaining hits were 
inspected for carboxylic containing side chains in close spatial proximity to cysteine 
residues.  However, this last criterion was not a stringent requirement because other 
residues might be able to act as nucelphiles. 
 Based on these criteria, 3 primary hits were selected for validation: E. Coli 
Cytidine Deaminase (CytD), E. Coli Uridine phosphorylase (UDP), and human KRas 
(Isoform 2B, 1-169). KRas did not show up in the initial proteomic screen using HEK 
293T cell lysates (unpublished data), but we did observe enrichment of other purine 
nucleotide handling enzymes. As described below, covalent modification was observed 
for both UDP and KRas, but not CytD.  Modificaion of KRas was characterized in detail.  
It was determined that the mechanism of KRas modification is similar to the mechanism 
previously shown for DDAH and E. Coli inosine monophosphate dehydrogenase 
(IMPDH, unpublished data).  Interestingly, we find that unlike these previous targets, the 
covalent adduct is not stable and susceptible to subsequent hydrolysis.  The effects of 4-
chloropyridine treatment on cells harboring oncogenic KRas and target engagement with 
KRas in cell culture are also evaluated. 
 
3.2 MATERIALS AND METHODS 
Materials 
Unless otherwise noted, all chemicals and reagents were purchased from Sigma- 
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Aldrich (St. Louis, MO, USA).  K2HPO4, Na2HPO4, NaH2PO4, and acetonitrile, were 
purchased from Thermo Fisher Scientific (Waltham, MA, USA).  
Cloning Escherichia Coli Cytidine Deaminase (CytD) 
E. Coli BL21(DE3) genomic DNA was isolated from 5 mL of an overnight 
culture, purified using QIAGEN DNeasy Blood & Tissue Kit (Qiagen; Valencia, CA, 
USA).  Polymerase Chain Reaction (PCR) amplification of the cytidine deaminase (cytd) 
from genomic DNA was carried out using the following primers, (gcytd-NdeI-For) 5’- 
TAC CAT ATG TTT CAC GCG TTG CAT AAT TAA-3’ and, (gcytd-XhoI-Rev) 5’- 
TAC CTC GAG TTA ATA TTT TGC TGT TCC GAG CAC-3’. Breifly, a PCR mixture 
containing 100 ng of genomic DNA, 200 uM dNTP’s, 25 pmol of primers, and 0.5 U 
Phusion HF polymerase in the manufacturer’s buffer (New England Biolabs; Ipswich, 
MA, USA) was thermocycled using a temperature program of 95 °C for 30 s, followed by 
20 cycles of 95 °C for 30 s, 50 – 60 °C (temperature gradient PCR) for 45 s, 72 °C for 90 
s and a final step at 72 °C for 10 min.  Successful amplification and purity of the PCR 
product was analyzed by 1% agarose gel stained with ethidium bromide.  The resulting 
PCR product at approximately 1.25 kb was gel purified using a QIAquick Gel Extraction 
Kit (Qiagen; Valencia, CA, USA).  The purified PCR product and a pET-28a expression 
vector were subjected to restriction enzyme digestion.  Breifly, 1 unit of NdeI and XhoI 
were incubated with 500 ng pET-28a and 1000 ng PCR product in manufacturer’s buffer 
at 37 °C for 2 h (New England Biolabs; Ipswich, MA, USA).  Digested samples were 
purified using the QIAquick PCR Purification Kit (Qiagen; Valencia, CA, USA). The 
digested PCR product and pET-28a samples were then ligated using 200 units of T4 
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ligase in manufacturer’s buffer (New England Biolabs; Ipswich, MA, USA) at a 1:3 ratio, 
respectively, for 18 h at 16 °C.  2 μL of the ligation reaction was transformed into 
electrocompetent BL23 (DE3) E. Coli cells and plated onto lysogeny broth (LB) agar 
plates with kanamycin (30 μg / mL). Several viable colonies were selected from the LB 
agar plates with kanamycin (30 μg / mL) after overnight incubation at 37 °C and regrown 
overnight as 5 mL cultures in the presence of kanamycin (30 μg / mL) at 37 °C. Plasmid 
from the regrown cultures was extracted and purified using a QIAprep Miniprep Kit 
(Qiagen; Valencia, CA, USA). DNA sequencing at the University of Texas DNA 
sequencing facility confirmed that the desired plasmid sequence matched that expected 
for E. Coli cdd (NCBI RefSeq: NP_416648.1).  
Expression and Purification of CytD 
Expression and purification of E. Coli CytD was carried out as previously 
described.7 No affinity tag was used in the purification of the E. Coli CytD construct.  
Expression and purification resulted in approximately 70% pure protein.   
Assay for CytD Enzymatic Activity and Inhibition by Halopyridines 
 Activity of partially purified E. Coli CytD was monitored by following the change 
in UV absorbance when a cytosine nucleoside was converted to uracil nucleoside as 
previously described.7 To monitor time-dependent irreversible inactivation, CytD (60 
μM) was pre-incubated with (1) and (2) (Table 1) (0-60 min, 2 mM).  Aliquots of the pre-
incubation mixtures were diluted 20-fold into excess cytidine substrate (10 mM) and 
monitored at 301 nm for 5 min.  
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Cloning Escherichia Coli Uridine phosphorylase (UDP) 
E. Coli BL21(DE3) genomic DNA was isolated from a 5 mL overnight culture 
and purified using QIAGEN DNeasy Blood & Tissue Kit (Qiagen; Valencia, CA, USA).  
PCR amplification of the uridine phosphorylase gene (udp) from genomic DNA was 
carried out using the following primers, (NdeI-EcUDP For) 5’-TAC CAT ATG TAT 
ATG TCC AAG TCT GAT GTT-3’ and (XhoI-EcUDP Rev) 5’- TAC CTC GAG GCG 
GGT AAA TTT ATG CAA CGC-3’. Breifly, a PCR mixture containing 100 ng of 
genomic DNA, 200 uM dNTP’s, 25 pmol of primers, and 0.5 units Phusion HF 
polymerase in the manufacturer’s buffer (New England Biolabs; Ipswich, MA, USA) was 
thermocycled using a temperature program of 95 °C for 30 s, followed by 20 cycles of 95 
°C for 30 s, 50 – 60 °C (temperature gradient PCR) for 45 s, 72 °C for 90 s and a final 
step at 72 °C for 10 min.  Successful amplification and purity of the PCR product was 
analyzed by 1% agarose gel stained with ethidium bromide.  The resulting PCR product 
at approximately 1.25 kb was gel purified using a QIAquick Gel Extraction Kit (Qiagen; 
Valencia, CA, USA).  The purified PCR product and a pET-28a expression vector were 
subjected to restriction enzyme digestion.  Breifly, 1 unit of NdeI and XhoI were 
incubated with 500 ng pET-28a and 1000 ng PCR product in manufacturer’s buffer at 37 
°C for 2 h (New England Biolabs; Ipswich, MA, USA).  Digested samples were purified 
using the QIAquick PCR Purification Kit (Qiagen; Valencia, CA, USA). The digested 
PCR product and pET-28a samples were then ligated using 200 units of T4 ligase in 
manufacturer’s buffer (New England Biolabs; Ipswich, MA, USA) at a 1:3 ratio, 
respectively, for 18 h at 16 °C.  2 μL of the ligation reaction was transformed into BL23 
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(DE3) E. Coli cells and plated onto LB agar plates with kanamycin (30 μg / mL). Several 
viable colonies were selected from the LB agar plates with kanamycin (30 μg / mL) after 
overnight incubation at 37 °C and regrown overnight as 5 mL cultures in the presence of 
kanamycin (30 μg / mL) at 37 °C. Plasmid was extracted and purified using a QIAprep 
Miniprep Kit (Qiagen; Valencia, CA, USA). DNA sequencing at the University of Texas 
DNA sequencing facility confirmed the desired insert sequence matched that expected for 
E. Coli udp (NCBI RefSeq NP_418275.1).  
Overexpression of Escherichia Coli  UDP 
500 mL of an E. Coli BL21(DE3) culture containing pET-28a-EcUDP was grown 
under agitation (250 RPM) at 37 °C until OD600 = 0.4-0.6 absorbance units in Lysogeny 
Broth containing 50 mg/L kanamycin and subsequently induced by adding 0.5 mM 
isopropyl-β-D-thiogalactoside (IPTG).  Growth was continued overnight at 37 °C with 
agitation (approx. 18 hr).  Bacterial culture was collected by centrifugation at 7,741 × g 
for 20 min, 4 C.  The cell pellet was either frozen in liquid nitrogen and stored at -80 °C 
or used fresh.   
The cell pellet was resuspended in 40 mL buffer containing 50 mM Tris, 100 mM 
KCl at pH 8, containing protease inhibitor cocktail (170 μg/mL phenylmethylsulfonyl 
fluoride (PMSF), 1 μg/mL pepstatin A, 1 μg/mL leupeptin).  The resulting cell slurry was 
sonicated and centrifuged at 39,191 × g to pellet then discard cell debris.  The remaining 
cell lysates were then assessed for total protein concentration via a Bradford assay and 
aliquots were flash frozen for storage.  
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E. Coli UDP Modification by 2- and 4-Chloropyridine Probes 
Cell lysates containing overexpressed E. Coli uridine phosphorylase (50 μg total 
protein)  were treated with 1 mM (1) and (2) at room temperature for 60 min. Replicate 
samples with exogenous uridine added (2 mM final concentration) were treated similarly.  
A ‘no-compound’ control was also run in parallel (43 μL total reaction volume).  
Following incubation, a biotin tag was selectively appended to the alkyne-bearing probe 
by the addition of N-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethyl]hexahydro-2-oxo-
(3aS,4S,6aR)-1H-thieno[3,4d ]imidazole-4-pentanamide (Biotin-PEO3-azide) (125 μM), 
tris(2-carboxyethyl)phosphine (TCEP, 1 mM), tris[(1-benzyl-1H-1,2,3-trazol-4-
yl)methyl]amine (TBTA, 100 μM), and CuSO4 (1 mM) bringing the final reaction 
volume to 50 μL.  After an additional 1 h incubation, samples were quenched with 
freshly prepared 2 × Laemmli buffer.  Samples were then subjected to sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed via Western Blot 
as described below. 
Site-directed Mutagenesis of KRas Isoform 2b (1-169)  
The pJExpress411 vector encoding an N-terminally His6-tagged recombinant 
human KRas (isoform 2, residues 1–169, based on construct used for PDB accession 
3GFT), containing a TEV cleavage site between the His6-tag and KRas gene, was 
generously provided by Daniel Gentile and Kevin Shokat (University of California San 
Francisco).8 This vector was used as a template for Quikchange site-directed mutagenesis 
(Stratagene).  For the C51A mutant, the primers were 5’-TGA TTG ATG GCG AAA 
CGG CCC TGT TGG ACA TCC TGG-3’and 5’-CCA GGA TGT CCA ACA GGG CCG 
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TTT CGC CAT CAA TCA-3’.  For the C118A mutation, the primers were 5’-AGA TGT 
ACC TAT GGT CCT AGT AGG AAA TAA AGC TGA TTT GCC TTC TAG A-3’ and 
5’-TCT AGA AGG CAA ATC AGC TTT ATT TCC TAC TAG GAC CAT AGG TAC 
ATC T-3’.   The C51A/C118A double mutant was constructed using the C118A primers 
on the C51A template.  The E3A/C118A double mutant was constructed using primers 
5’-TTT CCA GGG TAT GAC TGC GTA CAA ACT GGT TGT CG-3’ and 5’-CGA 
CAA CCA GTT TGT ACG CAG TCA TAC CCT GGA AA-3’ on the C118A template. 
The E49A/C118A double mutant was constructed using primers 5’-GTT GTG ATT GAT 
GGC GCA ACG TGC CTG TTG GAC-3’ and 5’-GTC CAA CAG GCA CGT TGC 
GCC ATC AAT CAC AAC-3’ on the C118A template. The E3A/E49A/C118A triple 
mutant was constructed using primers 5’-GTT GTG ATT GAT GGC GCA ACG TGC 
CTG TTG GAC-3’ and 5’-GTC CAA CAG GCA CGT TGC GCC ATC AAT CAC 
AAC-3’ on the E3A/C118A template. The E134A/C51A double mutant was constructed 
using primers 5’-GGC ATC CCG TTT ATC GCA ACG AGC GCG AAA AC-3’ and 5’-
GTT TTC GCG CTC GTT GCG ATA AAC GGG ATG CC-3’on the C51A template.   
 To construct the mutant genes a PCR mixture containing the vector template, the 
mutagenic primers, a dNTP mixture, and Phusion DNA polymerase in the manufacturer’s 
buffer (New England Biolabs; Ipswich, MA, USA) was thermocycled using a 
temperature program of 95 °C for 30 s, followed by 20 cycles of 95 °C for 30 s, 55 – 60 
°C for 1 min (temperature gradient PCR), 72 °C for 90 s and a final step at 72 °C for 10 
min. DpnI (New England Biolabs; Ipswich, MA, USA) was then added to the cooled 
reaction mixture and incubated at 37 °C for 2 h to digest the methylated template DNA. 2 
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μL of the resulting sample was transformed into electrocompetent E. Coli BL21 (DE3) 
Echerichia coli cells. Several viable colonies were selected from LB agar plates with 
kanamycin (30 μg / mL) after overnight incubation at 37 °C and regrown overnight as 5 
mL cultures in the presence of kanamycin (30 μg / mL) at 37 °C. Plasmid was extracted 
and purified using a QIAprep Miniprep Kit (Qiagen; Valencia, CA, USA). DNA 
sequencing confirmed the inserts contained the desired mutations and no other mutations.  
Expression and Purification of KRas Constructs 
An expression vector encoding an N-terminal hexahistidine-tagged recombinant 
human KRas (isoform 2, residues 1-169, based on construct used for PDB accession 
3GFT) was transferred into E. coli BL21 (DE3).  Bacterial culture was grown under 
agitation (250 RPM) at 37 °C until OD600 = 0.4-0.6 in Terrific Broth containing 50 mg/L 
kanamycin and subsequently induced by adding 0.5 mM isopropyl-β-D-thiogalactoside 
(IPTG).  Growth was continued overnight (approx 18 h) at 18 °C under agitation.  Cells 
were collected by centrifugation at 7,741 × g for 20 min, 4 °C.  The resulting bacterial 
pellet was flash frozen in liquid nitrogen and stored at -80 °C, or used freshly for the 
following purification. 
The pellet was resuspended in 25 mL of Lysis Buffer (20 mM Tris, 500 mM 
NaCl, 5 mM Imidazole at pH 8) supplemented with protease inhibitor cocktail (Roche 
complete EDTA free).  β-meracptoethanol (2 mM final concentration) was added to the 
solution and bacteria were lysed by sonication (210 s total, 10 s pulse on/45 s pulse off, 
70% amplitude).  Cell debris was pelleted by centrifugation at 39,191 × g for 20 min, 4 
°C and discarded.  The remaining supernantant was incubated for 1 h with 2 mL Qiagen 
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Ni-NTA resin slurry pre-equilibrated in Lysis Buffer.  The Ni-NTA resin was then 
transferred to a column and washed with 50 mL Lysis Buffer supplemented with 20 mM 
imidazole.  The hexahistidine-tagged recombinant human KRas was then eluted using 10 
mL Lysis Buffer supplemented with 200 mM imidazole.  The hexahistidine tag was 
cleaved using NHis6-TEV protease9 (1 mg recombinant TEV per 25 mg crude KRas, 1 
mg GDP added per 20 mg crude KRas) while dialyzing overnight against a buffer 
containing 20 mM Tris, 300 mM NaCl, 5 mM imidazole, 1 mM dithiothreitol (DTT) and 
0.5 mM EDTA.  Following dialysis, the cleaved protein was diluted five-fold with low-
salt buffer containing 20 mM Tris, 50 mM NaCl, pH 8.  The dialyzed solution was 
supplemented with 5 mM MgCl2 and 1 mM GDP. 2 mL of Ni-NTA resin pre-equilibrated 
with low-salt buffer was added to the solution and incubated for 1 hr to remove 
uncleaved protein and NHis-TEV.  The Ni-NTA resin was removed by centrifugation.   
The remaining protein solution was further purified using an 8 mL Q Sepharose 
Fast Flow column (GE Healthcare Life Sciences).  The column was washed using buffer 
containing 20 mM Tris, 100 mM NaCl at pH 8.  KRas was eluted with buffer containing 
20 mM Tris, 250 mM NaCl at pH 8.  The resulting protein solution was then subjected to 
filtration using an Ultracel 50 kDa MWCO filter (Amicon Ultra 4 Centrifugal Filter) in 
order to remove high molecular weight impurities in the filter. The KRas solution (flow-
through) underwent buffer exchange using an Ultracel 10 kDa MWCO (Amicon Ultra 4 
Centrifugal Filter) and 50 mL of buffer containing 10 mM Tris, 25 mM NaCl at pH 8.  
The final solution was concentrated to 1-2 mg/mL as assessed by Bradford assay (≥ 95% 
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purity).  Purified KRas yields ranged from 5-10 mg / 1 L culture.  All mutants used 
herein were purified using the same methodology. 
Stability of 2- and 4-Halopyridine Scaffold toward Nucleotides 
To determine the stability of the (1) and (2) at nuetral pH in the presense of 
guanine nucleotides, overnight (approx. 18 h) samples were incubated in buffer 
containing 50 mM KH2PO4 at pH 7.5. Samples containing each combination of pyridine 
compound ((1), (2), 1 mM) and nucleotide compound (GDP, GTP, 1 mM) were created 
along with control samples lacking nucleotide for each individual compound. 
High performance liquid chromatography (HPLC) was used to identify overnight 
reaction products. HPLC was carried using a Shimadzu Prominence analytical HPLC 
(Columbia, MD) equipped with two LC-20A pumps, a SIL-20A autosampler, a 
RF10AxL fluorescence detector, and a 5 μm, 4.6 x 50 mm Shimadzu-HPLC-TEST-C18 
column fitted with an Alltech Analytical Direct Connect- C18 guard column. 20 μL of an 
overnight incubation sample was injected using the autosampler. UV-Vis absorbance of 
the column eluate was monitored at wavelengths of 254 and 264 nm. Analyte separation 
was achieved using the following gradient program between solvent A (aqueous, 
potassium phosphate (100 mM) at pH 7.5, 10% acetonitrile, 0.1% trifluoroacetic acid 
(TFA)) and solvent B (80% acetonitrile). Solvent B was increased in a linear fashion 
from 0 % to 5 % over 5 min, to 25 % over the next 5 min, to 100 % over the next 1 min, 
held at 100 % for 2 min, and decreased to 5 % over the next 2 min. All solvents were 
degassed daily by bath ultrasonication for 30 min prior to use.  
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KRas Modification in vitro Characterization 
4-Chloro-2-((prop-2-ynyloxy)methyl)pyridine ((2), 100 μM) (4-Cl-Probe) was 
incubated with wildtype (wt) and mutant KRas (10 uM) in buffer containing 20 mM Tris, 
50 mM NaCl, and 10 μM GDP at pH 7.5, 25 °C for 1 h (43 μL total reaction volume).  
After 1 h a biotin tag was selectively appended to (2) by the addition of Biotin-PEO3-
azide (125 μM), tris(2-carboxyethyl)phosphine (TCEP, 1 mM), tris[(1-benzyl-1H-1,2,3-
trazol-4-yl)methyl]amine (TBTA, 100 μM), and CuSO4 (1 mM) bringing the final 
reaction volume to 50 μL.  After an additional 1 h incubation, samples were quenched 
with freshly prepared 2 × Laemmli buffer.  Samples were then incubated at 95 °C for 5 
min.  Upon cooling, samples were subjected to SDS-PAGE and analyzed via Western 
Blot as described below. 
The concentration dependent labeling of KRas was carried out analogous to that 
described above with the following minor changes.  Concentrations of (2) ranged from 0-
250 μM with an equimolar concentration of Biotin-PEO3-azide added to each sample 
during the click reaction.   
Experiments that evaluate whether KRas Isoform 2 (1-169) is covalently modified 
by (1) and (2) in the presence of excess guanosine diphosphate (GDP) and glutathione  
(GSH) were also carried out.  4-Cl-Probe, 100 uM or 4-chloro-2-((prop-2-ynyloxy)PO3-
Biotin)pyridine (4-Cl-PreClicked, 200 μM) was incubated with KRas (10 uM) in buffer 
containing 20 mM Tris, 50 mM NaCl, and 5 GDP or 5 mM GSH at pH 7.5, 25 °C for 1 h 
(43 μL total reaction volume).  For samples incubated with 4-Cl-Probe, a biotin tag was 
selectively appended to the alkyne-bearing probe as described above.  For samples 
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incubated with 4-CL-PreClicked, samples were quenched with 2 × Laemmli buffer.  
Samples were then incubated at 95 °C for 5 min.  Upon cooling, samples were subjected 
to SDS-PAGE and analyzed via Western Blot as described below. 
Overnight Dialysis of 4-chloropyridine probe modified KRas 
Two replicate samples containing (2) (500 uM) were incubated with KRas (10 
uM) in buffer containing 20 mM Tris, 50 mM NaCl, and 10 μM GDP at pH 7.5, 25 °C 
for 1 hr (750 μL total reaction volume). One replicate was then transferred to a dialysis 
bag (MWCO = 10 kDa) (Spectrum Labs, Inc., Rancho Dominguez, CA; #08-667B and 
dialyzed against 2 L of buffer for approx. 18 h at 4 °C.  The same procedure was carried 
out using the 4-CL-PreClicked compound.  After incubation for approximately 18 h at 4 
°C a biotin tag was selectively appended to (2) samples as described above. Samples 
were quenched with 2 × Laemmli buffer.  Samples were then incubated at 95 °C for 5 
min.  Upon cooling, samples were subjected to SDS-PAGE and analyzed via Western 
Blot as described below. 
KRas modification in MiaPaca2 cell culture 
Following treatment with (2) (100 μM) for 1 h.  MiaPaca2 (ATCC CRL-1420, 
pancreatic carcinoma cell line expressing KRas G12C) cell cultures were washed with 1 
× PBS, harvested, and resuspended in 20 mM Tris, 50 mM NaCl, 1% TritonX-100, at pH 
7.75.  Cell lysates were incubated with Biotin-PEO3-azide (125 μM), tris(2-
carboxyethyl)phosphine (TCEP, 0.5 mM), tris[(1-benzyl-1H-1,2,3-trazol-4-
yl)methyl]amine (TBTA, 50 μM), and CuSO4 (0.5 mM) for 1 h.  The Cu-catalyzed click 
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reaction was quenched with the addition of 500 μM EDTA.  Cell lysate samples (100 μL) 
were split into two replicate aliquots.  Input samples were mixed with 2 × Laemmli 
buffer.  Cold acetone (50 uL) was then added to the remaining aliquot.  Samples were 
vortexed and place on ice for 10 min and subsequently centrifuged at 16,000 × g for 10 
min at 4 °C.  The supernatant was carefully removed.  The protein pellet was 
resolubilized in 200 uL of Binding Buffer (0.1 M KH2PO4, 0.15 M NaCl at pH 7.5).  
Streptavidin slurry (Thermo Fisher Scientific; Waltham, MA, USA) (400 uL, 1:1) pre-
washed 3 × in binding buffer was added to each sample.  Samples were then incubated 
under gentle shaking for 1 hr at 4 °C.  Samples were then washed 4 × with Binding 
Buffer (2 min at 325 × g). 1.5 × Laemmli buffer was added to the resin and subsequently 
incubated at 95° C for 8 min. Samples were then subjected to SDS-PAGE and analyzed 
via Western Blot as described below.      
Cell Viability of MiaPaca2 and BxPC3 cells following 4-chloropyridine probe 
treatment 
MiaPaca2 and BxPC3 (ATCC CRL-1687, pancreatic adenocarcinoma cell line 
expressing KRas wt) cells were plated in 96-well plates at 2,000 cells per well in 90 ml 
Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS) and 
allowed to attach for 24 h. Cells were treated by the addition of 10 μl of 4-Cl-Probe to a 
final concentration of 1-100 μM or vehicle (0.1% DMSO final). After 24-72 h, media 
was exchanged and plates were analyzed using CellTiter-Blue Cell Viability Assay 
(Promega).  
 59 
Percentage of Covalent Modification of KRas in vitro 
 KRas (25 μM) was incubated with (2) (250 μM) or DMSO control as previously 
described above (see Methods: KRas Modification in vitro Characterization).  After 1 h a 
biotin tag was selectively appended to the (2) by the addition of Biotin-PEO3-azide (125 
μM), tris(2-carboxyethyl)phosphine (TCEP, 1 mM), tris[(1-benzyl-1H-1,2,3-trazol-4-
yl)methyl]amine (TBTA, 100 μM), and CuSO4 (1 mM).  After an additional 1 h 
incubation, the click reaction was quenched by addition of EDTA (1 mM, final 
concentration). Streptavidin agarose resin slurry (0.66 mL) (Thermo Fisher Scientific; 
Waltham, MA, USA) was then added to each sample and the total volume of each sample 
was adjusted to 1 mL using Binding Buffer ((0.1 M KH2PO4, 0.15 M NaCl at pH 7.5).  
Samples were incubated under gentle agitation for 1 h. The resin was washed 8 × with 
Binding Buffer.  Breifly, microtubes containing resin samples were brought up to 1.5 mL 
total volume with Binding Buffer and vortexed gently.  Resin was then pelleted by 
centrifugation and the supernatant was removed by pipetting.  Bound KRas was eluted 
from the resin upon addition of 1 × SDS-PAGE buffer and heating at 95 °C for 8 min to 
denature streptavidin.  Samples were subjected to SDS-PAGE and commassie staining. 
The percentage of modified KRas was approximated using densitometry analysis (Bio-
Rad Laboratories; Berkeley, CA).  
General Western Blot Procedure 
Western blots were performed by standard procedures using two primary 
antibodies, IgG fraction monoclonal mouse anti-biotin (1:200)  (Jackson 
ImmunoResearch, West Grove, PA; #200-002-211) and/or when applicable, a target 
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specific rabbit derived primary antibody (1:1000), coupled with the two-color Odyssey 
IR Dye Western Blot Kit I (Li-Cor Biosciences, Lincoln, NE; #926-31081), which 
contains IR Dye 800CW goat anti-mouse secondary antibody and IRDye 680CW goat 
anti-rabbit secondary antibody (1:10000). Images were scanned using an Odyssey 
Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE) at the core DNA Facility 
(University of Texas, Austin). 
 
3.3 RESULTS AND DISCUSSION 
To explore the utility of the halopyridine scaffold in targeting additional proteins 
of therapuetic and clincal interest, three proteins were chosen for individual 
characterization, two identified in the primary screen and one from accesory data.  Of the 
three individual proteins selected, halopyridine modification of human KRas was 
characterized in detail.  
Initial Selection and Characterization 
 From the primary proteomic screen, a variety of protein classes were identified as 
being modified by (1), (2), or both probes (Table 3.1). Categorizing the primary hits in 
terms of ligand binding slectivity revealed the majority (40%) of proteins identified were 
GTP/ATP binding proteins with the second major group (12%) identified being NAD+ 
binding proteins (Figure 3.1A). This analysis led to a hypothesis that halopyridines are 
somewhat selective for purine binding proteins or NAD+-binding proteins, a proposal that 
is under study. 
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Table 3.1 Structures of halopyridine probes used for validation of primary 
screening hits and characterization of KRas covalent modification. 
 
 
Figure 3.1 (A) E. Coli proteomic screening hits organized by binding  group. (Data 
collected by Joyce Er) (B) Criteria used for selection of preliminary hits for 
validation and characterization.  
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The first step towards development of this scaffold as a specific modifier is the 
validation of primary hits.  To increase the likelyhood of validating experimentally 
tractable targets of clinical interest, the hit list was filtered based on the critera introduced 
above. (Figure 3.1B) From the final list of hits, CytD and UDP were selected for 
characterization.  CytD’s clinical significance stems from its upregulation in certain 
adenocarcinomas and pancreatic cancers as well as its mutation-dependent role with 
respect to the efficacy of chemotherapuetic nucleoside analog treatments.10-13 Similarly, 
UDP1 activity is elevated in various tumor types and plays an important role in the 
activation of chemotherapuetic agents 5-fluorouracil and 5’-deoxy-5-fluorouridine via the 
pyrimidine salvage pathway.14-16 
 
Figure 3.2 Cysteine residues in close proximity to carboxylic side chains in the CytD 
crystal structure (PDB: 1AF2). (A) C129 and C132 coordinate the catalytic zinc in 
the active site (green) and nearby E104 (orange) hydrogen bonds with N3 of the 
product uridine (grey). (B) C217 (green) on the distal surface is flanked by D218 
and D256 (orange). 
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Both of these enzymes catalyze reactions involving pyrimidine nucelosides, 
cytidine or uridine, which resmeble the base halopyridine scaffold.  As revealed in the 
CytD crystal structure (PDB: 1AF2), CytD contains two potential sites that fullfill the 
proposed modification requirements by haloypridines. One site is located at the substrate 
binding pocket and the other on the surface. (Figure 3.2) The homohexamieric strucutre 
of UDP contains only one such site, near one of the regions essential for subunit-subunit 
contact.16 (Figure 3.3)  
Following expression and purification of CytD, covalent modification by either 
(1) or (2) was tested.  No modification by either probe was observed (data no shown). 
 
Figure 3.3 (A) Homohexameric structure of E. Coli UDP. (PDB: 1RXC) (B) C136 
(green) flanked by D133 and E135 shown in orange located near the subunit 
interface.  
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Steady state kinetic assays were also carried out to test for any change in enzymatic 
activity following pre-incubation with probe.  (Figure 3.4A) Again, no probe-dependent 
effect was observed.  Based on our inability to label and the absence of any significant 
change in kcat after pre-treatment, it was concluded that CytD was a false positive of the 
primary screen. 
Modification of UDP by (1) or (2) in crude lysates containing overexpressed UDP 
was also tested. Unlike CytD, UDP did show strong labeling via Western blot (WB). 
(Figure 3.4B) However, modification was not blocked by the presense of excess uridine, 
suggesting modification may not occur at the active site (Figure 3.4C).  
In parallel, modification testing was also carried out on KRas based on the 
abundance of purine nucleotide-binding proteins identified in the primary screen and 
 
Figure 3.4 (A) CytD steady state enzymatic rates following pre-incubation with 
probe compounds (1) and (2) (B) WB image and coomassie stain of UDP labeling by 
(1) (Lane 1) and (2) (Lane 2) in E. Coli lysates. (C) WB image and coomassie stain of 
UDP labeling by (1) (Lane 3) and (2) (Lane 4) in E. Coli lysates in the presence of 
excess UDP.  
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recent reports of successful covalent targeting of the oncogenic mutant KRas G12C.17-21  
Western blot analysis, as described below, revealed KRas as a validated target of 
halopyridines.  This result is of significant interest in light of the frustrating history of 
Ras inhibitor design efforts and may represent a new way to target KRas. For these 
reasons the modification of this important target by this novel scaffold was characterized 
in detail.  
KRas Modification Site Identification 
 
Figure 3.5 Cysteine residues in close proximity to carboxylic side chains in the KRas 
crystal structure (PDB: 4L8G). (A) C118 (purple) located near the nucleotide 
binding site, flanked by E143 and D119 (green). D119 coordinates to the guanine 
nucleobase. (B) C51 (purple) flanked by E3 and E49.  Switch I and II are 
highlighted in red and blue, respectively.  
In order to identify the residue(s) modified by (2), site-directed mutagenesis was 
carried out at the most likely positions, cysteine residues that are in close proximity to the 
acidic side chains of either glutamate or aspartate, but separated by enough space to 
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accommodate a pyridine ring.  KRas contains two such sites on its surface. (Figure 3.5)    
One is near the nucleotide-binding pocket at C118. Modification experiments carried out  
 using the purified C118A mutant still resulted in modification, albeit decreased 
compared to wildtype (Figure 3.6).  It was then postulated that KRas contains a second 
site of modification.  Therefore, a further mutation was carried out to create the double 
mutant KRas C51A/C118A (designated: DM).  Modification experiments using the DM 
resulted in loss of all observable labeling. In addition, a construct lacking cysteine 
residues (C51S/C80L/C118S) was also tested for modification (Figure 3.6).   This too 
resulted in loss of all observable labeling confirming that KRas can be modified at two 
distinct sites, C51 and C118, with what appears to be a higher propensity for modification 
at C118, although direct quantification was not assessed via Western blot.  
Figure 3.6 Western blot (lower) and accompanying coomassie gel (upper) of purified 
wild type and mutant constructs of KRas Isoform 2B (1-169) treated with (2). MW 
stands for Molecular Weight Marker (Fisher EZ-Run Prestained Rec Protein 
Ladder, Thermo Fisher Scientific, Waltham, MA, USA).  The MW bands represent 
17 kDa (lower) and 26 kDa (upper) reference proteins. 
There are drawbacks to modifying residues of KRas found in non-oncogenic cells.  
In contrast, by targeting a specific oncogenic mutation such as G12C, one can ensure 
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inhibition of only hyper-activated KRas without effecting normal KRas’ function in 
healthy tissue.  However, oncogenic KRas’ mutations take a variety of forms, many of 
which are not amenable to covalent targeting.22 Therefore having alternative means to 
covalently target KRas using an inherently selective scaffold is highly advantageous.   
Identification of Activating Residue(s) 
Each cysteine modification site is in close proximity to two carboxylate 
containing side chains that each have the potential to stabilize the protonated pyridine 
ring and prime it for nucleophilic attack at the 4- position.  The C51 site is neighbored by,  
 
Figure 3.7 (A) Western blot (lower) and accompanying coomassie gel (upper) of 
mutant constructs of KRas Isoform 2B (1-169) treated with (2). (B) Western blot 
(lower) and accompanying coomassie gel (upper) of mutant construct KRas Isoform 
2B (1-169) C118A E3A E49A (TM) treated with 2 or 3. MW stands for Molecular 
Weight Marker (Fisher EZ-Run Prestained Rec Protein Ladder, Thermo Fisher 
Scientific, Waltham, MA, USA).  The MW bands represent 17 kDa (lower) and 26 
kDa (upper) reference proteins. 
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glutamate residues E3 and E49.  Using the KRas C118A construct as a starting point, 
site-directed mutagenesis was used to obtain the individual mutants E3A and E49A as 
well as the double mutant E3A, E49A.  These constructs allowed us to study the 
influence of activating residues at a single site, C51.  Modification experiments using the 
C118A, E3A or C118A, E49A purified mutants resulted in labeling equal to that found 
using the C118A mutant. (Figure 3.7) This result suggested one of two possibilities.   
Either residues E3 and E49 are compensatory with regards to 4-Cl-probe activation or 
modification is the result of a different mechanism.  No modification was observed when 
the C118A, E3A, E49A mutant (designated: TM) was tested in vitro. As a control, 
incubation of the TM KRas with the fully activated 4-Cl-N-methyl-Probe (3), in which 
stabilization of the pyridinium form via protein binding is not necessary, resulted in 
strong labeling at C51 (Figure 3.7).  This indicates that stabilization of the protonated 
form by one or both the these residues (E3 or E49) is required for modification of KRas 
by 4-Cl-P. To address any gross changes in overall protein structure, each mutant 
construct used was tested for retention of the ternary complex KRasGDPMg2+ via 
native MS.  In all cases, the ternary complex was conserved indicating the mutant 
constructs maintained the overall protein structure compared to wildtype as reflected in 
their ability to bind GDP and Mg2+ (Figure 3.8).     
These experiments demonstrate a consistent mechanism for modification by (2), a 
cysteine in proximity to an activating carboxylate.  However, KRas differs in that, two 
carboxylates have compensatory function. This flexibility may be due to labeling on the 
surface of KRas as opposed to an active site. In the absence of significant steric 
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influences or non-covalent interactions with target, the halopyridine scaffold or the 
carboxylate residues may have multiple confirmations that can promote covalent 
labeling.  Future derivitization of the halopyridine scaffold to improve non-covalent 
interactions with KRas could influence which of these residues participate in activation.   
 
Figure 3.8 ESI mass spectrum of wild type and mutant constructs of KRas Isoform 
2B (1-169) sprayed from a 50 mM ammonium acetate solution (pH 7.8).  Spectrums 
were obtained under native spray conditions with static tip ionization, 1.4-1.7kV, 
capillary temperature 200°C. The complexes may contain numerous additional 
sodium, magnesium and ammonium adducts.  
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While KRas is known for its lack of obvious surface binding pockets to take advantage 
of, in this instance we achieve a unique selectivity due to fixed pairs of residues.  
Covalent Modification of KRas by the 4-Chloropyridine Probe is Labile Over Time 
Based on the Western blot detection of labeled KRas via detection of biotin 
appended to the probe the modification appeared to be stable under the conditions and 
time period tested.  However, based on the solvent exposed nature of the surface 
modification, it was possible that the modification could be susceptible to hydrolysis over 
longer time periods. To test this hypothesis, KRas was incubated overnight with excess 
(2) under dialysis conditions.  Loss of covalent modification was observed under dialysis 
conditions, but not in the control samples (no dialysis).  (Figure 3.9)  
These results suggest the covalent modification of KRas by (2) is labile over long 
time periods, likely due to hydrolysis of the S-C bond.  Since the probe is not very 
reactive in solution, in the control samples where excess probe is left in the mixture, new 
probe has the ability to replace any that hydrolyzes over time.  In contrast, under dialysis 
conditions, excess probe is removed and no new probe is present once hydrolysis occurs, 
thus leading to the loss of signal overnight.  The same result was seen when using (4), 
wherein the biotin moiety has previously been appended to the pyridine scaffold.  The 
use of (4) confirms that modification is not an artifact of the click reaction or  
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Figure 3.9 (A) Schematic representation of experimental setup. (B) Western blot 
(upper) and accompanying coomassie gel (lower) of wild type KRas Isoform 2B (1-
169) treated with 2 or 4. MW stands for Molecular Weight Marker (Fisher EZ-Run 
Prestained Rec Protein Ladder, Thermo Fisher Scientific, Waltham, MA, USA).  
The MW bands represent 17 kDa (lower) and 26 kDa (upper) reference proteins. 
experimental work-up, and confirms loss of label upon dialysis.  Our initial efforts to 
detect the hydrolyzed product were not successful, possibly due to due to low abundance 
of the expected product (data not shown). 
Probe Stability and Cu-click Chemistry Interference in the Presence of Excess GSH 
and GDP  
Here, we determine halopyridines are stable in the presence of GDP and if 
modification of KRas has any dependence on GDP concentration.  To investigate these 
 72 
questions in vitro, experiments were carried out testing the stability of the probe 
overnight and the modification of KRas in the presence of excess (5 mM) GDP or GSH.  
Based on previous evidence1, 2, it was hypothesized that neither experimental condition  
(overnight incubation or modification in the presence of GDP or GSH) would result in a 
different result.   Overnight incubation with GDP resulted in no observable change as 
monitored by HPLC, however, modification of KRas appeared to be inhibited by both 
GDP and GSH. (Figure 3.10, 3.11A)   To determine if GDP or GSH were inhibiting 
modification and not a different step in the experimental work up (4) was tested for its 
ability to modify KRas in the presence of GDP or GSH.  This would eliminate any false 
negative due to inhibition of the click reaction.  In contrast to the experiment above, use 
of (4) did result in modification. (Figure 3.11B)   These results suggest that the Cu(I)-
click reaction to append the biotin tag is inhibited by high concentration of GDP or GSH 
under these experimental conditions. However, treatment with (4) shows halopyridine 
covalent modification is even possible in the presence of these cellular effectors and that 











Figure 3.10 HPLC traces from overnight incubations of 2- and 4-chloropyridine 





Figure 3.11 (A) Western blot (lower) and accompanying coomassie gel (upper) for 
labeled KRas in the presence of increasing concentrations of GDP. (B) Western blot 
and accompanying coomassie gel for KRas labeled with the biotin pre-clicked probe 
(4) in the presence of effectors GDP and GSH. MW stands for Molecular Weight 
Marker (Fisher EZ-Run Prestained Rec Protein Ladder, Thermo Fisher Scientific, 
Waltham, MA, USA).  The MW bands represent 17 kDa (lower) and 26 kDa (upper) 
reference proteins. 
Modification of Endogenous KRas in MiaPaca2 Cell Culture 
 Part of a probe compounds usefulness is its ability to modify its target in cells, so 
we assessed target engagement in cell culture. MiaPaca2 cells, a pancreatic carcinoma 
cell line, were chosen for use because 90% of pancreatic tumors harbor a KRas mutation, 
but the majority of these tumors do not contain the G12C mutation.21 Therefore, 
validating a potential means to target other oncogenic KRas mutants would be of 
significant benefit. To determine whether KRas could be modified in cultured cells, 
MiaPaca2 cell cultures were treated with media containing (2) (100 μM) or vehicle 
control (DMSO) for 1 h. Cells were subsequently washed and harvested using standard 
procedures and cells were lysed by brief sonication.  Biotin-PEO3-azide, TCEP, TBTA 
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and CuSO4 were added to lysate samples as described and incubated for an additional 1 h.  
The Cu-catalyzed click reaction was then quenched by addition of EDTA.  Cellular  
Figure 3.12 (A) Western blot for KRas in MiaPaca2 cell lysates treated with 2 or 
DMSO. (Left) Cell lysate input  showing equal loading and (Right) KRas detection 
following streptavidin agarose enrichment.  MW stands for Molecular Weight 
Marker. 
proteins labeled by the probe were enriched on streptavidin agarose.  The resulting 
enrichment was probed for KRas via Western blot.  The results of this experiment 
demonstrate that the (2) does covalently modify KRas in cultured cells, suggesting it is 
cell permeable and is able to engage its target. (Figure 3.12)   
Interestingly, there is a small shift in the mobility of the input sample and 
enriched sample.  Small, unexpected shifts in the electrophoretic mobility of Ras 
isoforms have also been observed elsewhere.  These shifts have been shown to correlate 
to single Ras point mutations and in other cellular studies, possibly reflect increased post-
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translational processing.23, 24 While not directly investigated here, it is possible that 
modification of KRas by (2) interferes with KRas processing or that additional 
modification in the hyper variable region (not present in the plasmid construct) cause the 
observed shift. While the exact nature of this shift was not determined, no other bands are 
apparent in either sample to suggest non-specific binding of the antibody is occurring.   
Based on the previous reports of shifts in KRas’ electrophoretic mobility due to 
small structural changes and the lack of any non-specific binding of the antibody in 
whole cell lysates, these experiments demonstrated target engagement in intact cultured 
cells.  This suggests the halopyridine scaffold has the potential to be used as a starting 
point for covalent targeting of KRas in a cellular context. 
Cell Proliferation in the presence of 4-chloropyridine probe 
Figure 3.13 MiaPaca2 cell viability following treatment with 100 μM (2) for 72 h.   
KRas functions as a cell-signaling switch through protein-protein interactions in 
response to external stimuli.  Labeling at the C51 or C118 site may have an influence on 
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the ability of KRas to bind its downstream partners.  It was recently shown that small 
molecule labeling at C118 on the Ras:SOS complex can be used to prevent the reloading 
of Ras with GTP in vitro.25  This represented a new approach to Ras pathway inhibition, 
however, these compounds utilized a highly reactive maleimide to target C118.  The use 
of (2) could represent a way to target this same site, using a much more selective 
electrophilic fragment.  
To determine if labeling of KRas in MiaPaca2 cells had any effect on cell 
proliferation, cell viability assays using CellTiter-Blue were conducted. Viability was 
assessed at 0, 24, 48, and 72 h at treatments with (2) over a concentration range of 0.1 – 
1000 μM. In MiaPaca2 cells, treatments with (2) at 100 μM resulted in very modest, but 
statistically significant, decreases in viable cells at 72 h. (Figure 3.13) To make sure this 
decrease in viability was due to decreased cell growth and not to cell death due to toxicity 
at the time of treatment, viability was monitored at several time points (0 – 72 h).  It was 
determined that no significant cell death occurred upon treatment and is consistent with 
(2) the probe not being inherently toxic in cell culture (data not shown).  This modest 
effect could also suggest that modified KRas does not disrupt signaling, only a small 
fraction of KRas is covalently modified, or other signaling pathways resulting in 
proliferation may be activated in response to probe treatment.   
In vitro quantification of modified KRas 
 In order to address one of the possible reasons for the lack of a strong functional 
effect on cell viability, the fraction of KRas covalently labeled in vitro was determined.  
Analogous to treatment of cell culture, recombinant KRas was treated with 100 μM 4-Cl-
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Probe for 1 h. Biotin-PEO3-azide, TCEP, TBTA and CuSO4 were added to each sample 
as described and incubated for an additional 1 h.  The Cu-catalyzed click reaction was 
then quenched by the addition of EDTA. Labeled KRas was enriched using streptavidin  
 
Figure 3.14 (A) In vitro streptavidin enrichment of KRas treated with (2) or DMSO. 
Triplicate coomassie stained gels. (B) Densitometry measurements of coomassie 
stained gels in A. MW stands for Molecular Weight Marker (Precision Plus Protein 
All Blue Prestained Protein Standards, Bio Rad, Hercules, CA, USA).  The MW 
bands represent 25 kDa (upper), 20 kDa (middle) and 15 kDa (lower) reference 
proteins. 
agarose. To directly assess the extent of labeled protein the resulting enrichment was 
analyzed by SDS-PAGE and visualized by coomassie staining.  Enrichment of probe-
treated KRas only resulted in a small percentage (approx. 11%) of labeled protein as 
compared to the experimental input (Figure 3.14). Therefore covalent targeting of KRas 
using 4-halopyridines only occurs to a minor extent.  
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 The observation that only a small fraction of KRas is modified by (2) may be 
partly a consequence of labeling at the surface of the protein. A key determinant in the 
covalent modification of proteins by 4-halopyridines is the ability to stabilize the 
pyridinium form.  With respect to DDAH, this stabilization takes place in the active site 
away from bulk solvent.  While structurally divergent from DDAH’s native substrates, 
steric constraints imparted by the active site in conjunction with interaction of Asp66 
(PaDDAH) with the pyridinium form to orient the 4-carbon for attack most likely 
contributes to the significantly faster and more efficient modification of DDAH 
compared to KRas.1,2  The influence of these active site dependent constraints on 
modification are lost at the surface of the protein.  Multiple residues that may serve to 
activate the probe are present near the sites of modification on KRas, but without the 
addition of other favorable interactions imparted by the target-binding site, the 
interactions that lead to stabilization of the active probe would be expected to be transient 
in nature.  This has important implications for further development of 4-halopyridine 
based probes.  When modifying at the surface of the protein, there may be limits to how 
much affinity can be improved through non-covalent interactions because of the lack of 
structural features to take advantage of as described.  In these cases, the use of both target 
specific derivitization to the extent it may be applied at the surface as well as modulation 
of the pyridinium switch to increase reactivity (as discussed in Chapter 2) will be 




 Three clinically relevant enzymes (CytD, UDP and KRas) were tested for their 
ability to be labeled by (1) and (2).  Only one of the two enzymes selected from the initial 
proteomic screen (UDP) was validated as a target.  The 4-chloropyridine probe also 
labeled KRas, which was tested based on its therapeutic interest and structural properties.  
It was demonstrated that the 4-chloropyridine probe uses a similar modification 
mechanism with KRas as previously shown for DDAH and has the ability to label both 
C51 and C118.  Unexpectedly, the adduct was shown to be unstable and susceptible to 
hydrolysis overnight.  Experiments in MiaPaca2 cell culture demonstrate KRas can also 
be modified in cultured cells.  Treatment of cells, even at high concentrations of 4-
chloropyridine probe, only resulted in very modest decreases in MiaPaca2 cell 
proliferation.  One possible reason for the modest effect is incomplete KRas modification 
illustrated by the in vitro tests. Scaffold optimization will be essential to increase both the 
percentage of KRas labeled and to enhance any functional downstream effect of KRas 
targeting.  These results illustrate a conserved mechanism for selectively targeting 
cysteine residues with neighboring carboxylates and represent a promising start for KRas 
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Chapter 4: Characterization of the Catalytic Activity of PaDDAH 
T165L and it’s Application Toward ADMA Quantification  
 
4.1 INTRODUCTION  
The methylated arginines, asymmetric Nω- Nω-L-dimethylarginine (ADMA), Nω-
monomethyl-L-argnine (NMMA) and symmetric Nω- Nω-L-dimethylarginine (SDMA) are 
produced by the degradation of post translationally methylated proteins.  In cells, both 
ADMA and NMMA act as endogenous inhibitors of all three forms of Nitric Oxide 
Synthase (NOS).  NOS is responsible for synthesis of nitric oxide (NO), a short-lived 
signaling molecule that initiates diverse signaling cascades based on tissue type.1-3 In the 
endothelium, NO helps to maintain vascular homeostasis.4 Because of its central role in 
regulating blood pressure, proper NOS function is of utmost importance. To date, several 
regulatory mechanisms of NOS activity have been uncovered.  
One such mechanism is regulation of ADMA and NMMA levels through their 
catabolism by the enzyme dimethylarginine dimethylaminohydrolase-1 (DDAH-1). 
While ADMA and NMMA can be eliminated by renal excretion, the vast majority is 
catabolyzed by DDAH-1.5 So, DDAH serves an important role as an indirect regulator of 
NOS.  Interestingly, DDAH-1 activity has been shown to be decreased during oxidative 
stress, a cellular condition commonly associated with cardiovascular disease.  This 
decrease in DDAH1 activity is concomitant with ADMA accumulation.6-8 And while 
impairment of the NOS pathway is multifactorial, increased levels of circulating ADMA 
have been suggested to play a role in endothelial dysfunction.9 The exact role ADMA 
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plays is still a matter of debate, but regardless of if it is a causative agent or a byproduct 
of cardiovascular disease progression, research in this area has led to the understanding 
that the concentration of circulating ADMA can be used as an independent biomarker, 
with strong prognostic value, for cardiovascular morbidity and total mortality.10    
As both a biomarker for and possible mediator of cardiovascular disease, ADMA 
quantification is of significant clinical interest.11 Currently, the three most established 
methods for quantification of ADMA are HPLC, LC-MS, and ELISA each of these 
methods has its own distinct advantages and disadvantages.12 In the case of HPLC and 
LC-MS, both of these methods have the advantage of being able to simultaneously 
quantify not only ADMA, but NMMA and SDMA as well. While often requiring sample 
enrichment (LC-MS, HPLC) and/or pre-column derivitization (HPLC), these methods are 
considered the most reliable analysis methods. Unfortunately, these methods also require 
instrumentation that may not be available or is prohibitively expensive depending on the 
clinical setting.13 Comparatively, ELISA kits utilizing an anti-ADMA antibody can 
quantify ADMA in a plate based format using common laboratory equipment, and do not 
require sample enrichment, but do require derivitization (N-acylation). Unfortunately, this 
analysis method can suffer from matrix dependent effects (comparison of plasma/serum 
samples vs. standard controls) relegating its effective use to clinical investigations in 
which groups of samples are compared and the endpoint is the shift in ADMA 
concentrations in response to an interviention.13   
ADMA quantification methods require a high level of both sensitivity and 
accuracy due to the low concentrations of ADMA that need to be quantified (0.3-0.7 μM 
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for healthy individuals, ≥ 1 μM for at risk individuals) and the observation that even 
slightly elevated concentrations are correlated with cardiovascular risk.13 For example, 
even a 0.13 μM increase in ADMA levels was correlated with a 21% risk increase in 
cardiovascular disease.14 Again, the significant risk associated with even these small 
deviations demonstrates the importance of methods that can accurately and precisely 
determine ADMA concentrations as well as the difficulty in comparing values derived 
from different quantification methods.  Progress continues to be made, but improved 
methods to quantify ADMA are of interest.  
Based on preliminary characterization of Pseudomonas aeruginosa DDAH 
(PaDDAH) T165L conducted by Dr. Tom Linsky and Dr. Corey Johnson in our 
laboratory, it has been proposed herein that this specific mutant may be applicable as a 
tool for ADMA quantification.  Briefly, through investigation of the role of Thr165 in the 
catalytic mechanism it was found that PaDDAH T165L had a dramatic effect on 
catalysis.15 The mutant PaDDAH T165L was shown to be covalently inactivated by its 
own substrate in a time-dependent manner. Mass spectrometry studies indicated the 
possible formation of a thiocarbamate adduct which is only hydrolyzed slowly and much 
less efficiently than the normal thiouronium adduct (Scheme 4.1).  Because of PaDDAH 
T165L’s partitioning between substrate turnover and self-inactivation, in conjunction 
with the slow rate of hydrolysis to regenerate the resting enzyme, we hypothesize here 
that this mutant represents a means by which ADMA, its natural substrate, can be 
quantified. Specifically, the percentage of inactivated PaDDAH  
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T165L after incubation with a sample containing ADMA should be proportional to the 
amount of ADMA present in the given sample. Following incubation of PaDDAH T165L 
with ADMA samples, a signal amplification step can be used to quantify the remaining 
activity of PaDDAH T165L, representing a method that is not dependent on expensive 
instrumentation, is inherently specific for methylated argnines, and has the potential to be 
more cost-effective than ELISA (Figure 4.1).   
In this chapter, a methodology to quantify ADMA using PaDDAH T165L is 
developed.  The experimental partition ratios for ADMA, NMMA, and SMTC are 
measured and proof-of-principal experiments that demonstrate the feasibility of this 
approach are preformed.  To the best of our knowledge, this is the first time a mutation-
induced inactivation partitioning has been applied to quantify a substrate, which in this 
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case is a clinically relevant biomarker. Each step in this method is experimentally 
optimized in order to maximize accuracy and sensitivity. Although rigorous validation of 
the proposed method will be required prior to clinical use, the experiments presented here 
support our hypothesis that the unique partitioning of PaDDAH T165L can be utilized 
for quantification of a clinically significant biomarker.  During the development of this 
method, insights into the mechanisms governing self-inactivation were also revealed. 
 
Figure 4.1 ADMA quantification using PaDDAH T165L workflow. The method is 
composed of three individual steps, (1) Incubation of PaDDAH T165L with the 
sample of interest. (2) Sample aliquot dilution into a secondary incubation 
containing excess substrate S-Methyl-L-thiocitrulline (SMTC) and 7-diethylamino-
3-(4-maleimidophenyl)-4-methylcoumarin (CPM). (3) Fluorescence measurement 
for the quantification of the reaction of methanethiol with CPM (Excitation λ: 384 
nm, Emission λ: 470 nm).   
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4.2 MATERIALS AND METHODS 
Materials 
Unless otherwise noted, all chemicals and reagents were purchased from Sigma-
Aldrich (St. Louis, MO, USA).  K2HPO4, Na2HPO4, NaH2PO4, dimethylsulfoxide 
(DMSO) and trifluoroacetic acid (TFA) were from Thermo Fisher Scientific (Waltham, 
MA, USA). 96-well and 384-well black bottom polystyrene microplates were from 
Corning (Corning, NY, USA). Expression and purification of each PaDDAH mutant was 
carried out as previously described.16 
Construction of Vector for PaDDAH T165L, C249S  
  
The pET-28a vector with N-terminally His6-tagged recombinant PaDDAH  
T165L, was previously cloned by Tom Linsky.16 This vector was used as a template for 
Quikchange site-directed mutagenesis (Stratagene; La Jolla, CA, USA).  For the C249S 
mutant, the primers were 5’- GAC GGC GGC GTC AGT AGC ATG TCG CT-3’and 5’- 
AGC GAC ATG CTA CTG ACG CCG CCG TC -3’.  To construct the mutant genes, a 
PCR mixture containing the template vector, the mutagenic primers, a dNTP mixture, and 
Phusion DNA polymerase in the manufacturer’s buffer (New England Biolabs; Ipswich, 
MA, USA) was run using a temperature program of 95 °C for 30 s, followed by 20 cycles 
of 95 °C for 30 s, 55 – 60 °C for 1 min (temperature gradient PCR), 72 °C for 90 s and a 
final step at 72 °C for 10 min. DpnI (New England Biolabs; Ipswich, MA, USA) was 
then added to the cooled reaction mixture and incubated at 37 °C for 2 h to digest the 
methylated template DNA. 2 μL of the resulting sample was transformed into BL21 
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(DE3) Echerichia coli cells. Viable colonies were selected from Lysogeny Broth (LB) 
agar plates with kanamycin (30 μg / mL) after overnight incubation at 37 °C. Plasmid 
was extracted and purified using a QIAprep Miniprep Kit (Qiagen; Valencia, CA, USA). 
Mutations were confirmed by DNA sequencing of the insert sequence.   
Determination of Partition Ratios for Substrates ADMA, NMMA, and SMTC 
 Partition ratios, defined as the number of moles of product per mole enzyme 
inactivated, were determined for each substrate using the COLDER protocol to quantify 
L-citrulline formation.  The partition ratio for SMTC was also determined using the 
continuous CPM based fluorescence assay utilizing the synthetic substrate SMTC. 17,18  
To determine partition ratios, purified recombinant PaDDAH T165L (0.3-1 μM) 
was incubated with the substrate of interest (ADMA, NMMA, or SMTC, 1 mM) in Assay 
Buffer (KCl (100 mM), Na2HPO4 (100 mM), EDTA (0.05 mM), and Tween20 (0.01% 
w/v) at pH 6.5) at 25 C (100 μL total reaction volume). At varying time points (0-180 
min) reactions were quenched with 10 μL of 6 N TFA and analyzed for L-ctirulline 
production as previously described.17 All experiments were run in triplicate in a 96-well 
plate format.  To determine the partition ratio (y0), the calculated turnover number versus 
time plots were fit to the exponential decay function below using Kaleida Graph 
(Synergy Software, Reading, PA).  Variables are defined as follows: 𝑃; Number of 
turnovers, 𝑦!; Partition Ratio, 𝐴; burst phase amplitude, 𝑘𝑜𝑏𝑠; observed inactivation rate, 
t; time. 
𝑃   = 𝑦! + 𝐴 ∙ 𝑒!!!"#∙!  (Eq. 3.1) 
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pH Dependence on Enzyme Reactivation from the Thiocarbamate Adduct 
 
To test the pH dependence of PaDDAH T165L activity, experiments were set up 
as outlined above for partition ratio determination using the COLDER assay.  Assay 
conditions were equivalent for all experiments, excluding pH adjustments.  Experiments 
were carried out at pH values 6.5 and 7.5.  Data were fit to the following equation to 
model burst phase and steady state turnover at pH 7.5. ).  Variables are defined as 
follows: 𝑃; Number of turnovers, 𝑦!; Partition Ratio, 𝐴; burst phase amplitude, 𝑘𝑜𝑏𝑠; 
observed inactivation rate, t; time, m; steady state turnover. 
 
𝑃   = 𝑦! + 𝐴 ∙ 𝑒!!!"#∙! +𝑚 ∙ 𝑡 (Eq. 3.2) 
Blood Plasma Sample Preparation 
ADMA standard solutions (0 – 2.5 μM) or human blood plasma samples from 
normal and arteriosclerosis donor backgrounds were obtained from a commercial vendor 
(ProteGenex, Inc.; Culver City, CA, USA).  2 mL Acetonitrile (ACN) was added to each 
1 mL plasma sample to precipitate proteins.  Samples were vortexed for 2 min and 
centrifuged to pellet insoluble material (16 × g, 10 min).  The resulting supernatant was 
transferred and split between 3 microtubes.  The samples were concentrated to dryness 
under vacuum at 45 °C.   At this point, some samples were tested as is after reconstitution 
in Assay Buffer.  Samples were then reconstituted in phosphate buffered saline (PBS; 137 
mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) at pH 7.4.  Samples were 
enriched for methylated arginines by solid phase extraction (SPE) using Oasis MCX 1cc 
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vacuum cartridges (Waters Coorporation; Milford, MA,USA).  Briefly, samples were 
applied to the SPE column, washed with 1 mL 100 mM HCl and 1 mL MeOH 
sequentially.  Bound small molecules were then eluted using a freshly prepared solution 
of 50% MeOH/40% H2O/10% concentrated NH4OH (v/v/v).  The eluted samples were 
again concentrated to dryness under vacuum at 45 °C.  The final samples were 
reconstituted in Assay Buffer (80 uL total volume, concentrated approx 12.5-fold).  
General Assay Procedure 
The methodology developed was based on the following steps. (1) Incubation of 
PaDDAH T165L with the ADMA containing. (2) The incubation was then diluted into a 
secondary incubation containing excess SMTC and 7-diethylamino-3-(4-
maleimidophenyl)-4-methylcoumarin (CPM).  (3) Fluorescence measurement for the 
quantification of the product methanethiol reacting with CPM (Excitation λ: 384 nm, 
Emission λ: 470 nm).  The raw RFU signal versus time data was fit to equation 3.1 in 
order to determine the relative fluorescence units (RFU) end point.  Calculated end points 
were used as is or converted to number of turnovers per enzyme and plotted versus 
ADMA μM. 
Assay Optimization 
In order to determine the parameters, concentrations, and incubation times needed 
for ADMA quantification in clinical samples, PaDDAH T165L (10 – 500 nM) was 
incubated with various concentrations of ADMA (0-150 uM) in Assay Buffer.  At 
varying time points (0-18 h) aliquots (25 or 50 μL) were diluted into a solution (30 or 60 
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μL) containing SMTC (0.5 - 2 mM), CPM (20 – 200 μM), and DMSO (5 - 10%) in Assay 
Buffer. Fluorescence was measured (every 30 – 90 sec) for a total of 20 min.  The final 
parameters chosen for testing of clinical samples were: [PaDDAH T165L] = 250 nM, 
[ADMA] ≥ 5 μM (after sample enrichment), Incubation time = 3 h, [SMTC] = 545 uM, 
[CPM] = 60 μM, and 9% DMSO. 
ADMA Quantification in EDTA Stabilized Blood Plasma Samples 
Blood plasma samples were prepared for use as described above.  PaDDAH 
T165L was added to each enriched plasma sample or a standard ADMA solution to a 
final concentration of 0.25 μM (80 uL total volume).  Samples were incubated at 25 °C 
for 3 h.  25 μL was pipetted into a 384-well black bottom polystyrene microplate.  30 μL 
of substrate solution containing SMTC (1 mM), CPM (110 μM), and DMSO (10%) was 
added to each well using an Rainin® AutoRep E repeater pipette (Mettler-Toledo LLC, 
Columbus, OH, USA).   The final concentrations for all components were 0.114 μM 
PaDDAH T165L, 545 μM SMTC, 60 μM CPM, and 9% DMSO.  Each sample or 
standard was run in triplicate.  Fluorescence was read on a Wallac Victor 1420 Plate 
Reader (PerkinElmer; Waltham, MA, USA) equipped with filters for excitation at 340 nm 
and emission at 470 nm.  
 
4.3 RESULTS AND DISCUSSION 
Previously, Dr. Tom Linsky, carried out site-directed mutagenesis at Thr165 to 
learn more about the role this residue played in catalysis.  His results indicated Thr165 
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might not play a significant role in the reaction. However, one of the mutants tested, 
T165L, slowly became inactivated when incubated with substrate (SMTC and ADMA).15  
Herein, the potential utility of PaDDAH T165L as a tool to quantify the clinically 
important biomarker ADMA was evaluated.  Through method development and 
optimization, further insights on the mechanism of inactivation are also revealed. 
Determination of Substrate Partition Ratios 
 In order to develop an ADMA quantification methodology using PaDDAH 
T165L, experimental determination of the partition ratio(s), for each substrate, was 
needed. This partition ratio describes the number of moles of product per mole enzyme 
inactivated and is essential to determine the assay conditions needed to achieve 
observable inactivation.    Previously, Dr. Tom Linsky had estimated the partition ratio of 
SMTC based on ratios of rate constants derived from global fitting of kinetic data.16 
Herein, the partition ratios for ADMA, NMMA, and SMTC were all determined 
experimentally based on quantifying product formation over time.  Experiments were 
carried out using excess substrate at three different enzyme concentrations (0.3, 0.5, and 
1 μM).  The final concentration of L-citrulline produced was used to determine the 
number of turnovers per enzyme at varying time points (Figure 4.2).  The partition ratio 
was shown to be independent of total enzyme concentration, an important factor with 
respect to its ability to quantify ADMA (vide infra).   
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Figure 4.2 Determination of partition ratio (y0) for (A) ADMA, (B) NMMA, and (C) 
SMTC. Turnovers per enzyme with respect to time as determined by the COLDER 
assay with T165L DDAH (1 μM) at pH 6.5 were plotted for each substrate.  (A) 
ADMA data fit to a single exponential with A = -75 ± 2, kobs = 2.3 ± 0.2 × 10-2, and y0 
= 78 ± 2. (B) NMMA data fit to a single exponential with A = -77 ± 2, kobs = 1.8 ± 0.1 
× 10-2, and y0 = 80 ± 2. (C) SMTC data fit to a single exponential with A = -69 ± 2, kobs 
= 3.8 ± 0.3 × 10-1, and y0 = 73 ± 1. 
Determination of partition ratios for all three substrates also provided potential 
clues as to the nature of substrate inactivation and if substrate partitioning takes place at a 
common step in all three cases.  If different partition ratios were found for each substrate, 
this difference might suggest partitioning occurs at a step influenced by different 
substrate substituents.  The partition ratios (product formed: inactivated enzyme) for 
ADMA (78 ± 2 :1) and NMMA (80 ± 2 :1) are within error suggesting a common portion 
step (Figure 3.1).  SMTC was observed to have a slightly lower partition ratio at 73 ± 1: 
1.  This might suggest a different partition step for SMTC, however, this decreased value 
could also arise from another factor (see below).  The burst phase for SMTC is much 
more rapid than that of ADMA or NMMA.20 In fitting to equation 3.1, the derived kobs is 
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approximately 30-fold higher for SMTC and reaches an end point value in approx. one 
tenth of the time.  Because no terms in the equation take into consideration reactivation of 
the enzyme, which may take place to a minor extent over the timescale of the reaction 
(180 min), any reactivation would be reflected in a reduction in kobs and an approximate 
increase in the partition ratio (y0).  
While the differences in the calculated partition ratios of ADMA, NMMA and 
SMTC were outside of error, we believe the differences are due to reactivation and not 
different partitioning steps (see below).  Based on the current experimental data, a single 
partitioning step is proposed that takes place upon collapse of the second tetrahedral 
intermediate (Scheme 4.1).  Here we suggest a mechanism where by the T165L mutant 
could cause this inactivation. The bulkier leucine residue may influence the conformation 
of the active site histidine (H162).  If the protonated His is positioned closer to the δ-
nitrogen in the mutant (T165L), this could activate the δ-nitrogen as a leaving group 
promoting the loss of L-ornithine and formation of the thiocarbamate adduct. Regardless 
of mechanism, these experiments revealed the necessary details for application of 
PaDDAH T165L for ADMA quantification.  Specifically, we demonstrated that in bulk 
solution, on average, under these experimental conditions, PaDDAH T165L is 
inactivated approximately once every 80 turnovers when ADMA or NMMA is used as 
substrate.  When SMTC is used as substrate, inactivation is completed at a much faster 
rate than when ADMA or NMMA is used (20 min versus 180 min).  This information is 
essential for determining the working concentration of PaDDAH to use in the assay to 
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ensure both observable inactivation and sufficient signal during the signal amplification 
step. 
Influences on PaDDAH T165L Reactivation 
 Previous mass spectrometry evidence suggested the formation of a common 
inhibitory thiocarbamate adduct (+ 42 Da) when either SMTC or ADMA was used as the 
substrate.15 A slow reactivation rate was assigned to hydrolysis of this long-lived adduct. 
In order to accurately quantify ADMA it would be advantageous to completely eliminate 
or at least minimize the amount of enzyme that undergoes this reactivation reaction 
during the time period of the assay. Identifying what factors influence PaDDAH T165L 
reactivation following adduct formation would allow us to control these potentially 
complicating factors during method development.   
 It was hypothesized that, if the enzyme adduct is hydrolyzed to regenerate the 
active enzyme, the pH of the solution should have an influence on the rate of reactivation.  
To test the effects of pH, partition experiments were repeated at pH 7.5.  These 
experiments revealed that reactivation of T165L was increased at higher pH, as reflected 
by the increase in steady state enzyme turnover at longer time periods when the data was 
fit to equation 3.2 (Figure 4.3).  
Unexpectedly, the increased steady state rate of turnover at higher pH was 
different for each substrate (ADMA > NMMA > SMTC).  This was an unexpected result 
since, mass spectrometry evidence suggested that a common 42 Da adduct accumulates 
over time when either SMTC or ADMA was used as the substrate.  If the adduct is the 
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same, why do we observe different reactivation rates?  Furthermore, this unidentified 
influence on enzyme reactivation rates is substrate specific.   
 
 
Figure 4.3 Influence of pH on steady state turnover for (A) ADMA, (B) NMMA, and 
(C) SMTC. Turnovers per enzyme with respect to time as determined by a uriedo 
assay with T165L DDAH (1 μM) at pH 6.5 (o) and 7.5 (l) were plotted for each 
substrate and fit to equation 3.2. (A) ADMA steady state turnover at pH 7.5, m = 
0.45 ± 0.01 min-1. (B) NMMA steady state turnover at pH 7.5, m = 0.27 ± 0.01 min-1. 
(C) SMTC steady state turnover at pH 7.5, m = 0.12 ± 0.02 min-1.  
We reasoned that the alkyl-containing product (methanethiol, methylamine, or 
dimethylamine) produced during normal turnover might accelerate reactivation.  If this 
were true, nucleophilic attack by the product (methanethiol, methylamine, or 
dimethylamine) at the thiocarbamate carbon would contribute to the increased rate of 
reactivation to different extents, explaining the observed differences. Dr. Tom Linsky had 
previously shown that the adduct was susceptible to attack by hydroxylamine, but these 
experiments were conducted with high (mM) concentrations of hydroxylamine, well 
above the concentrations of product that would be produced during hydrolysis of ADMA 
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at the concentrations of PaDDAH T165L used (3 - 5 μM).16  Because ADMA showed the 
highest steady state reactivation rates, we tested whether the addition of exogenous 
dimethyl amine, now at lower concentrations, to SMTC-inactivated T165L could increase 
the rate of steady state turnover.  SMTC inactivated PaDDAH T165L was used because 
of its relatively low basal reactivation rate as compared to ADMA inactivated PaDDAH 
T165L.  Addition of dimethylamine at the concentrations expected to be produced (70 
uM) during inactivation under our assay conditions did not result in any change in 
reactivation of the enzyme.  Moreover, at double the concentration expected to be 
produced, a slight negative effect was seen (Figure 4.4A).  From these experiments, we 
concluded that the presence of the alkyl-containing product did not have an effect on 
enzyme reactivation.  
 Another factor that was unique in each experimental sample was the identity of 
the excess substrate present in the inactivation mixture.  To test whether the identity of 
the excess substrate had any effect on reactivation, T165L was again inactivated using 
SMTC at pH 7.5.  Aliquots of inactivated enzyme were then diluted into excess ADMA, 
NMMA, or SMTC.  Reactions were quenched at varying time points and the partition 
ratio was calculated.  In these experiments, three unique steady state rates were observed 
(Figure 4.4B).  The rates of reactivation were closely related to the steady state rates 
observed in the original experiments at pH 7.5. These results suggest that substrate 
binding to inactivated protein, either at the active site or at an allosteric site, are the most 




Figure 4.4 Influence of dimethylamine and excess substrate identity on steady state 
L-Citruline production. (A) SMTC-inactivated T165L in the presence of excess 
SMTC and dimethylamine (l) or no dimethylamine control (o) at pH 7.5. (B) 
SMTC-inactivated T165L in the presence of excess SMTC (l), ADMA (o), or 
NMMA (u). Steady state L-Citrulline production in the presence of SMTC at pH 
7.5 fit to a line with y-intercept = -5.6 ± 1.4 and slope m = 0.13 ± 0.01 min-1. Steady 
state L-Citrulline production in the presence of NMMA at pH 7.5 fit to a line with y-
intercept = 3.0 ± 0.4 and slope m = 0.20 ± 0.01 min-1. Steady state L-Citrulline 
production in the presence of ADMA at pH 7.5 fit to a line with y-intercept = -0.1 ± 
1.3 and slope m = 0.33 ± 0.01 min-1. 
Unlike the human DDAH1 isoform, PaDDAH is known to dimerize with an 
apparent Kd ~500 nM.19 Substitution of residues R40 and R98 to glutamate and histidine, 
respectively, shifts the equilibrium position towards the monomer.  In the monomeric 
form, PaDDAH (E40, H98) still retains greater than 95% activity suggesting that 
cooperativty between active sites in the dimer form is unlikely.  Still, the lack of 
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cooperativity in the enzyme does not exclude the possibility that binding of substrate to 
one T165L monomer may induce small active site rearrangements in the paired T165L 
monomer, which might better position the adduct for hydrolysis. Alternatively, it may be 
possible for substrate to bind to the same active site with the adduct and induce 
rearrangements dependent on the identity of the substrate. Recently obtained 
crystallographic data is currently being reviewed to determine possible active site 
rearrangements induced by the T165L mutation, the possibility of T165L cooperativity or 
‘half-sites’ reactivity in the dimer form, and whether or not substrate is able to bind at the 
active site already containing the thiocarbamate adduct. 
Determining what influences enzyme reactivation rates was of significant 
importance with respect to developing a PaDDAH T165L ADMA quantification method.   
Based on these results, the pH of assay samples should be kept low (pH 6.5) and the 
products of normal enzyme turnover are not expected to effect reactivation at the 
concentrations produced. Additionally, the fact that SMTC displays the lowest rate(s) of 
reactivation is advantageous for signal amplification and endpoint analysis.  Furthermore, 
if future study finds that dimerization has an influence on the rate of reactivation, use of a 
monomer form of PaDDAH T165L (Triple mutant: T165L, E40, H98) may represent a 
means to further improve the robustness of the assay.  
Proof of Principle Demonstrating Application of PaDDAH T165L for ADMA 
Quantification 
To test for the ability of PaDDAH T165L to be inactivated by ADMA in a 
concentration dependent manner, PaDDAH T165L (0.5 μM) was incubated with varying 
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concentrations of ADMA (0 – 150 μM) for 3 h.  Aliquots of each sample were transferred 
to a 96-well plate containing SMTC (545 μM) and CPM (60 μM) and the fluorescence  
   
Figure 4.5 ADMA concentration dependence on remaining activity of PaDDAH 
T165L. (A) Reactions of T165L (0.114 μM) with SMTC (545 μM) upon rapid 
dilution following 1 h pre-incubation with various concentrations of ADMA (0; + , 
25; ¯  , 50; × , 75; o  , 150 μM; l), fit to equation 3.1. (B) Turnovers/Enzyme as a 
function of the concentration of ADMA in pre-incubation mixture fit to a line with 
y-intercept of 78.5 ± 2 and slope of -0.15 ± 0.03. 
was monitored every 90 s for 20 min.  The results demonstrate that the end point of the 
fluorescence assay decreases as the concentration of ADMA in the original sample 
increases (Figure 4.5A).  Plotting the assay end point fit as a function of ADMA reveals a 
linear relationship over the concentration range tested (Figure 4.5B).  Additionally, the 
apparent partition ratio calculated here, in the absence of ADMA, is in good agreement 
with the partition ratio calculated using the color-developing reagent (COLDER) to 
derivitize and quantify the urea group of the L-Citrulline product.  These results 
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demonstrate the ability to discriminate various ADMA concentrations utilizing T165L’s 
unexpected catalytic partitioning and provided evidence for further method development 
based on these principles. 
Evaluation of PaDDAH T165L Sample Incubation Conditions  
 Upon demonstrating the ability of PaDDAH T165L to be inactivated by ADMA 
in a concentration dependent manner, we sought to optimize the methodology for 
quantification of ADMA in clinical samples.  Ideal properties of an ADMA 
quantification method would include the ability to quantify ADMA directly from the 
sample of interest (e.g. blood plasma or serum). Concentrations of ADMA in blood 
plasma are in the low micromolar range, much lower than the concentrations used in the 
proof of principle experiments above. Still, based on PaDDAH T165L’s specificity for 
ADMA, and its slow rate of reactivation we sought to evaluate if differences could be 
observed at these low concentrations of ADMA. 
 To test if PaDDAH T165L could be used to discriminate ADMA levels at the 
concentrations found in blood plasma, PaDDAH T165L (15 nM) was incubated with 
varying concentrations of ADMA (0 – 2.5 μM) for 18 h. Aliquots of each sample were 
transferred to a 96-well plate containing SMTC (545 μM) and CPM (60 μM) and the 
fluorescence was monitored every 90 s for 20 min total.  End point RFU values were 
calculated using equation 3.1 and plotted as a function of ADMA concentration (Figure 
4.5).  Compared to the experimental conditions above (See: Proof of Principle for 
PaDDAH T165L ADMA Quantification), a reduction in enzyme concentration was 
required in order to ensure each enzyme molecule would undergo an adequate number of 
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turnovers to promote inactivation as defined by the partition ratio.  Samples were 
incubated overnight to account for the low reaction velocity at concentrations below KM. 
These experiments also revealed a linear correlation between fluorescence signal and 
ADMA concentration (Figure 4.6).  However, the slope of this line is on the same order  
of magnitude as the average standard deviation between triplicate samples tested (-7200: 
6800).  Therefore, skipping a concentration step under these conditions will not result in 
sufficient accuracy for clinical samples and suggests the concentration or enrichment of  
Figure 4.6 End point RFU from reactions of T165L (15 nM) with SMTC (545 μM) 
upon rapid dilution following 18 h pre-incubation with various concentrations of 
ADMA (0 – 2.5 μM). The RFU values were plotted against ADMA concentration 
and fit to a line with y-intercept 3.4 ± 0.3 × 105 RFU and a slope of -0.7 ± 0.1 × 105 
RFU / ADMA μM.  
ADMA from blood plasma samples will be needed for accurate quantification. 
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To test the minimal concentration of ADMA needed for accurate and sensitive 
quantification, PaDDAH T165L (0 - 500 nM) was incubated with varying concentrations 
of ADMA (0 – 75 μM) for 0-5 h. Aliquots of each sample were transferred to a 96-well 
plate containing SMTC (545 μM) and CPM (60 μM) and the fluorescence was monitored 
every 90 s for 20 min total.  Based on the analysis of these experiments, a minimum of 5 
μM of ADMA was needed for accurate quantification.  This would entail a ten-fold 
enrichment of ADMA.  Sample concentration to this degree is possible through 
centrifugal evaporation with or without solid phase extraction. 
Sample Preparation and Evaluation of ADMA in Human Blood Plasma  
 To prepare samples for centrifugal evaporation, 2 mL acetonitrile was added to 
each 1 mL blood plasma sample in order to precipitate proteins that might interfere with 
the signal amplification step.  Following centrifugation, the supernatant was removed and 
subjected to centrifugal evaporation using a speed vacuum instrument. Samples were 
reconstituted in 80 μL Assay Buffer and were incubated with 0.25 μM PaDDAH for 3 h. 
Aliquots (25 μL) of each sample were transferred to a 384-well plate containing SMTC 
(545 μM) and CPM (60 μM) and the fluorescence was monitored every 90 s for 20 min 
total (Figure 4.7A).    
These tests revealed differential signals between control human blood plasma and 
human blood plasma with an arteriosclerosis medical background (ProteGenex, Inc.; 
Culver City, CA, USA).  However, the fit values lie out of range of expected values when 
compared to the standard curve and do not reach an end point over the same timescale at 
the standard solutions. These results could indicate a background reaction of free plasma 
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thiols (e.g. glutathione, cysteine, and homocysteine) with CPM. The total concentration 
of free thiols in blood plasma can be as high as 10 μM, ten fold higher than that of 
ADMA, and would complicate the assay.21   Additionally, the amount of unwanted 
 
Figure 4.7 Evaluation of assay design in human blood plasma samples levels. (A) 
RFU as a function of time following pre-incubation with reconstituted plasma 
samples. (Arteriosclerosis; o  , Control; l). (B) Standard curve produced using 
ADMA in Assay Buffer.  End point values for Control (4.0 ± 0.5 × 106 RFU) and 
Arteriosclerosis (3.6 ± 0.4 × 106 RFU) do not correlate with the standard curve.   
reaction of plasma free thiols and CPM may be further complicated by other medical 
conditions of the individuals from whom the samples were taken.  For example, elevated 
levels of homocysteine have also been identified as a marker for atherosclerosis.22 If not 
properly adjusted for, these background contributions may result in overestimation of the 
concentration of ADMA.  While it was encouraging to see differentiation between 
control samples and those with a cardiovascular disease background (arteriosclerosis) the 
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plasma dependent effects limit the usefulness of this methodology (in its current form) in 
the same way as has been reported for ADMA quantification using ELISA.  Specifically, 
matrix dependent effects limit the ability to accurately quantify samples based on a 
standard curve and often lead to an overestimation of ADMA levels.13 
Figure 4.8 Evaluation of blood plasma samples and standard solutions of ADMA 
following SPE treatment. (A) Standard curve produced by standard solutions of 
ADMA (0 – 2.5 μM). (B) Sample dependent background signal over the timescale of 
the assay following SPE treatment (Arteriosclerosis; o  , Control; l , Buffer; ×). (C) 
Background corrected RFU as a function of time following pre-incubation with SPE 
treated plasma samples. (Arteriosclerosis; o  , Control; l).  
These limitations prompted us to test whether or not incorporating solid phase 
extraction could improve or eliminate the background signal associated with direct 
sampling of reconstituted blood plasma.  In theory, solid phase extraction using a cation 
exchange resin, such as the Oasis MCX SPE cartridges (Waters Coorporation; Milford, 
MA,USA), should result in the selective isolation of basic amino acids and concomitant 
elimination of unwanted free thiols.  In order to assess any other effects based on addition 
of the SPE protocol, standard solutions of ADMA (0 – 2.5 μM) were also treated in the 
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same way for direct comparison.  Once reconstituted in Assay Buffer following 
centrifugal evaporation of the SPE eluent, samples were assayed as the blood plasma 
samples described above.   
The results of these experiments revealed enrichment and concentration of 
standard solutions (0 – 2.5 μM) by centrifugal evaporation and SPE treatment can 
achieve observable differentiation (Figure 4.8A) Furthermore, SPE does not introduce 
additional background signal within the standard solutions.  To test whether or not 
plasma samples still maintain significant background signal following SPE treatment, 
fluorescence of plasma sample incubations lacking SMTC were monitored for 20 min.  
These experiments showed a significant contribution to background signal from plasma 
components even after SPE.  Furthermore, the background signal was observed to be 
condition dependent (Figure 4.8B).  When background corrected, a similar result is 
observed as seen when assaying samples without SPE pre-treatment. Specifically, 
differences in control and arteriosclerosis samples are observed, but the values do not 
correlate to the expected concentration range as defined by the standard curve (Figure 
4.8C).  
 These sample-dependent background contributions are a major challenge in the 
development of a PaDDAH T165L based assay for ADMA quantification because, as 
presented, the inactivation of PaDDAH T165L is ADMA specific, but the final 
fluorescence readout is indiscriminate of the source of the thiol.  Currently, the 
methodology described here has the potential to be suitable for investigations in which 
groups of samples are compared and the endpoint is the shift in ADMA concentration in 
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response to an intervention.  Still, possible solutions to these problems are currently being 
evaluated to extend the method’s usefulness to absolute quantification of ADMA 
concentration.   For example, pre-treatment of samples with a non-fluorescent thiol 
reactive molecule such as N-ethylmaleimide (NEM) could minimize the background 
signal contribution.  However, sample dependent effects make addition of a standardized 
amount of compound for pre-treatment unreliable as excess NEM could compete with 
CPM for reaction with methanethiol.  Alternatively, pre-treatment with a thiol scavenging 
resin (Sigma Aldrich, St. Louis, MO, USA, Cat# 569909) could eliminate the influence 
of plasma thiols in a sample independent manner.  Further development of this assay 
along with a direct comparison of the method outlined here with a commercially 
available ADMA ELISA Kit ALX-850-323-K101 (Enzo Life Sciences, Inc., 
Farmingdale, NY, USA) is underway.23 
 Based on our results, it is likely further improvement will be required to increase 
the sensitivity and accuracy of this methodology for clinical use.  Comparison to the 
current standards of clinical measurement during continued optimization, especially with 
the only other plate-based methodology (ELISA), will be an essential part of the 
evaluation of our assay. While ELISA is currently the most accessible method for 
quantification, the cost-savings associated with production and use of a recombinant 
PaDDAH T165L based assay compared with using α-ADMA monoclonal (or polyclonal) 
antibodies (Ab) for ADMA quantification would be significant.24, 25 With small increases 
in sensitivity and accuracy, a PaDDAH T165L based assay has the potential to overcome 
the limitations of analytical methods (HPLC/LC-MS) in terms of accessibility and 
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represents a significant cost reduction with respect to plate based consumable reagents 
(PaDDAH T165L vs. α-ADMA Abs). 
Comparison to Other Examples of Substrate Inactivation 
 The result that PaDDAH T165L slowly becomes inactivated when incubated with 
substrate was unexpected, but the observation of substrate inactivation is not completely 
novel.  Substrate inactivation of enzymes haw also been reported elsewhere.  Meely and 
Martin reported the substrate dependent inactivation of brain Glutamate Decarboxylase 
(GAD).26,27 The authors proposed that through the GAD’s decarboxylation dependent 
transamination mechanism, the substrate glutamate promotes formation of inactivated 
enzyme via dissociation of the co-factor PLP.  This mechanism is proposed to contribute 
to the physiological regulation of GAD, which involves a cycle of formation of 
apoenzyme and its reactivation to holoezyme by binding PLP.27 Substrate induced 
inactivation has also been reported for E. Coli N-acetylmuramoyl-L-alanine amidase 
(AmiD). In this case, transient-substrate induced inactivation was interpreted in terms of 
conformational isomerization of the enzyme in the presence of substrate.28 However, 
compared with our studies, both of these mechanisms of inactivation are shown to be 
non-covalent in nature and are a function of natural regulation of enzyme activity.  
 Substrate inactivation of mutant enzymes has also been reported elsewhere and in 
one case was discovered as a result of site directed mutational studies probing the 
substrate specificity of FEZ-1 metallo-β-lactamase, a study directly analogous to the one 
that led to the characterization of PaDDAH T165L.29 In this example, evidence suggested 
that the replacement of active site Y228 with alanine in FEZ-1 changes the position of the 
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subsrate in the catalytic pocket. This allows a direct interaction between C200 and the 
hydrolyzed substrate leading to the formation of a covalent and irreversibly inactivated 
complex. Inactivation of a specific point mutant enzyme during steady state turnover has 
also been reported for the diheme enzyme MauG (P107V) from Paracoccus 
denitrificans.30 Here, the point mutation enhances the rate of a detrimental oxidative side 
reaction most likely caused by altered positions of amino acids at the heme site.   
These studies, along with our own, suggest that catalytic partitioning of mutant 
enzymes is not limited to enzymes that use covalent intermediates, nor is it limited to 
enzymes that require cofactors.  In all three cases, these branched pathways were 
discovered unexpectedly through active site mutational analysis.  However, our work 
represents a novel advance in that this is the first time an unexpected substrate 
partitioning has been applied to quantify a substrate.  The discovery of mutation-induced 
inactivation partitioning in a variety of enzyme classes suggests that it may be possible to 
use mutagenesis to purposefully engineer enzymes for substrate inactivation and 
quantification purposes for a wider array of small molecules.  
 
4.4 CONCLUSIONS 
 In this chapter, a methodology for ADMA quantification using the catalytic 
partitioning of PaDDAH T165L was explored.  The experimental partition ratios for 
DDAH’s endogenous substrates (ADMA and NMMA) and the synthetic substrate SMTC 
are defined.  Based on this data and the proposed assay workflow, a methodology to 
quantify ADMA was developed.  The method outlined was tested for the ability to 
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quantify ADMA in clinically-relevant blood plasma samples.  Differences in signal 
amplification were seen between control plasma and those from individuals with an 
arteriosclerosis medical background.  However, sample-dependent background 
contributions did not allow for absolute quantification of ADMA by use of a standard 
curve, although optimization of the protocol is continuing.  The results described here 
show the feasibility of using PaDDAH T165L as a means to quantify ADMA, but the 
assay must be further optimized and other complicating factors must be accounted for if 
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Figure A.1 L-Citrulline standard curve using the color-developing reagent 
(COLDER) to derivatize the urea group of the L-Citrulline product  The data was 
fit to the line y = 1.15 ± 0.03 × 10-1 + 8.65 ± 0.04 × 10-3. 
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Figure A.2  Standard curve for the reaction of free thiol with CPM in a 96-well plate 




Figure A.3  Standard curve for the reaction of free thiol with CPM in a 384-well 




Figure A.4 Incubation time dependence on remaining activity of PaDDAH T165L. 
(A) RFU as a function of the concentration of ADMA in pre-incubation mixtures 
assayed at various time points (65 min; + , 90 min; ¯  , 120 min; × , 180 min; o  , 
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